<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2025.1640224</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Exploring research trends in cancer immunotherapy via single-cell technologies: a scientometric perspective</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes" corresp="yes">
<name>
<surname>Li</surname>
<given-names>Zhongxun</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2408132/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Han</surname>
<given-names>Qi</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2369522/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huang</surname>
<given-names>Zimu</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Sen</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1965931/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Guo</surname>
<given-names>Huina</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2702432/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Hongliang</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2262774/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Guan</surname>
<given-names>Xiaoya</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2432176/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Li</surname>
<given-names>Hairong</given-names>
</name>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Zhang</surname>
<given-names>Chunming</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, First Hospital of Shanxi Medical University</institution>, <addr-line>Taiyuan</addr-line>,&#xa0;<country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Shanxi Province Clinical Medical Research Center for Precision Medicine of Head and Neck Cancer, First Hospital of Shanxi Medical University</institution>, <addr-line>Taiyuan</addr-line>,&#xa0;<country>China</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Shanxi Medical University</institution>, <addr-line>Taiyuan</addr-line>,&#xa0;<country>China</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Department of Otolaryngology Head and Neck Surgery, First Hospital of Shanxi Medical University</institution>, <addr-line>Taiyuan</addr-line>,&#xa0;<country>China</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>Department of Cell Biology and Genetics, The Basic Medical School of Shanxi Medical University</institution>, <addr-line>Taiyuan, Shanxi</addr-line>,&#xa0;<country>China</country>
</aff>
<aff id="aff6">
<sup>6</sup>
<institution>Department of Histology and Embryology, Shanxi Medical University</institution>, <addr-line>Taiyuan</addr-line>,&#xa0;<country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2514113/overview">Jiaheng Xie</ext-link>, Central South University, China</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Micha&#x142; Zarobkiewicz, Medical University of Lublin, Poland</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1410705/overview">Xin Wu</ext-link>, Central South University, China</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Zhongxun Li, <email xlink:href="mailto:lizhongxun2020@sxent.org">lizhongxun2020@sxent.org</email>; Hairong Li, <email xlink:href="mailto:lihairong20030829@163.com">lihairong20030829@163.com</email>; Chunming Zhang, <email xlink:href="mailto:zcmsxmu@sxent.org">zcmsxmu@sxent.org</email>
</p>
</fn>
<fn fn-type="equal" id="fn003">
<p>&#x2020;These authors have contributed equally to this work</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>22</day>
<month>08</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="collection">
<year>2025</year>
</pub-date>
<volume>16</volume>
<elocation-id>1640224</elocation-id>
<history>
<date date-type="received">
<day>03</day>
<month>06</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>07</day>
<month>08</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2025 Li, Han, Huang, Zhang, Guo, Liu, Guan, Li and Zhang.</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Li, Han, Huang, Zhang, Guo, Liu, Guan, Li and Zhang</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Introduction</title>
<p>Cancer immunotherapy has brought new therapeutic hopes for cancer patients, but it is complex in its mechanism of action, and there are significant individual differences, which restricts its wide use. As single-cell analysis technology develops rapidly, it provides an innovative research approach to investigate immunotherapy mechanisms, to identify potential biomarkers, and to optimize individualized treatment strategies.</p>
</sec>
<sec>
<title>Methods</title>
<p>The Core Collection of Web of Science (WOSCC) was used to retrieve and obtain relevant literature related to &#x201c;application of single cell sequencing in cancer immunotherapy&#x201d; since the establishment of the WOSCC. A quantitative analysis and visualization of the related literature was conducted using tools such as Bibliometrix, Excel, CiteSpace, VOSviewer, and Scimago Graphica.</p>
</sec>
<sec>
<title>Results</title>
<p>The total number of related literatures included was 4856, with an average annual growth rate of 25.14%. According to published articles, China and the United States lead the field. Frontiers in immunology, Nature Communications, Journal for Immunotherapy of Cancer, Scientific Reports, Frontiers in Oncology and Cancers have an important academic influence in this field. Research hotspots focus on tumor immune microenvironment and cellular heterogeneity. Research trends such as spatial transcriptomics, standardized processes, and T cell function are becoming increasingly popular.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>In tumor immunotherapy, single-cell sequencing is profoundly changing the research paradigm. It not only improves our understanding of the immune microenvironment and therapeutic heterogeneity, but also assists us in identifying accurate markers and formulating individualized treatment plans.</p>
</sec>
</abstract>
<kwd-group>
<kwd>immunotherapy</kwd>
<kwd>tumor immune microenvironment</kwd>
<kwd>heterogeneity</kwd>
<kwd>single-cell RNA sequencing</kwd>
<kwd>bibliometrix</kwd>
</kwd-group>
<counts>
<fig-count count="8"/>
<table-count count="2"/>
<equation-count count="0"/>
<ref-count count="51"/>
<page-count count="20"/>
<word-count count="10422"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Cancer Immunity and Immunotherapy</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Immunotherapy has emerged as one of the most effective cancer treatment strategies, owing to its strong specificity, fewer adverse effects, and capacity to induce immune memory&#x2014;advantages that set it apart from traditional therapeutic approaches. Notably, the advance immune checkpoint inhibitors and chimeric antigen receptor T cell therapy has markedly enhanced the prognosis of patients with diverse forms of advanced malignant tumors (<xref ref-type="bibr" rid="B1">1</xref>&#x2013;<xref ref-type="bibr" rid="B3">3</xref>). Nevertheless, the clinical application of immunotherapy remains challenging due to several limitations, including primary resistance in some patients, rapid relapse following an initial therapeutic response (acquired resistance), and the occurrence of potentially severe immune-related adverse events (<xref ref-type="bibr" rid="B4">4</xref>). Due to the complexity of cellular composition and the heterogeneity of functional states within the tumor microenvironment (TME), conventional molecular techniques often fall short in accurately capturing these features.</p>
<p>With unprecedented resolution, single-cell omics technologies&#x2014;especially single-cell RNA sequencing (scRNA-seq)&#x2014;have recently enabled detailed characterization of the cellular composition, functional states, and intercellular communication networks of immune cell subsets within TME (<xref ref-type="bibr" rid="B5">5</xref>). Through single-cell profiling of tumor-infiltrating lymphocytes, dendritic cells, and tumor-associated macrophages, researchers have uncovered the dynamic trajectories of T cell exhaustion, immunosuppressive signatures of myeloid populations, and identified novel immune subpopulations and key molecular markers closely associated with immunotherapy efficacy. For instance, Zheng et&#xa0;al. conducted a single-cell sequencing analysis of tumor-infiltrating lymphocytes from hepatocellular carcinoma patients, revealing marked heterogeneity in functional states and clonal expansion, which was strongly correlated with treatment response (<xref ref-type="bibr" rid="B6">6</xref>). In another study, Cheng et&#xa0;al. constructed a comprehensive transcriptomic atlas of myeloid cells across multiple cancer types, highlighting the pivotal immunoregulatory roles of LAMP3<sup>+</sup> dendritic cells and VEGF<sup>+</sup> macrophages (<xref ref-type="bibr" rid="B7">7</xref>). The integration of single-cell multi-omics technologies&#x2014;such as single-cell ATAC sequencing (scATAC-seq), Cellular Indexing of Transcriptomes and Epitopes by sequencing (CITE-seq), and spatial transcriptomics&#x2014;is progressively enabling a three-dimensional, dynamic reconstruction of the cancer immune ecosystem. This advancement offers robust support for the design and refinement of precision immunotherapy strategies. As the volume of literature in this domain continues to grow rapidly, there is an increasing need for systematic approaches to delineate research trajectories, identify thematic hotspots, and predict future directions.</p>
<p>Scientometric analysis, which applies mathematical and statistical methods to the study of scholarly literature, offers a systematic perspective on the evolution of specific research fields and unveils their structural characteristics. It enables the visualization of shifting research frontiers and facilitates the quantitative assessment of contributions made by countries, institutions, and individual scholars (<xref ref-type="bibr" rid="B8">8</xref>). Moreover, it aids in identifying emerging themes and potential future directions. In recent years, the convergence of single-cell technologies and immunotherapy in oncology has emerged as a prominent interdisciplinary research focus. Accordingly, this study employs scientometric approaches to explore and visualize the research landscape of single-cell analysis in the context of tumor immunotherapy. The goal is to provide researchers with a macro-level understanding of the field&#x2019;s development, highlight forward-looking research topics and key technological pathways, and ultimately promote advances in both basic science and clinical application.</p>
</sec>
<sec id="s2" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="s2_1">
<title>Data collection and retrieval strategies</title>
<p>Web of Science Core Collection (WoSCC) is a comprehensive academic database covering over 190 subject areas globally. It is widely recognized as the superior database for bibliometric research in various disciplines, providing excellent literature retrieval and citation analysis services (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B10">10</xref>). A comprehensive search of WOSCC was conducted to identify literature related to single-cell analysis in antitumor immunotherapy, covering all records since the database&#x2019;s inception. To minimize potential bias due to ongoing updates of the database, all searches were performed on the same day. The search strategy was as follows: TS = (&#x201c;immune therapy&#x201d; OR immunotherapy OR immunity OR immunotherapies) AND TS = (cancer* OR tumor* OR carcinoma* OR neoplasm*) AND TS = (&#x201c;single-cell analysis&#x201d; OR &#x201c;single-cell RNA*&#x201d; OR &#x201c;single-cell near/3 sequencing&#x201d; OR &#x201c;single-cell transcriptomic&#x201d; OR &#x201c;single-cell near/3 profiling&#x201d; OR &#x201c;single-cell omics&#x201d;). The following types of documents were excluded (1): non-English publications; (2) early access articles, book chapters, retracted publications, conference proceedings, and data papers.</p>
<p>A total of 4,856 documents were retrieved for further analysis, including 4,481 research articles and 375 review articles. For each publication, the following metadata were extracted: title, publication year, authors, country/region, affiliated institutions, source journal, keywords (including author keywords and keyword plus), citation count, number of references, references and abstract. Journal impact factors were primarily obtained from the 2023 edition of the Journal Citation Reports (JCR). For journals without JCR data, <xref ref-type="supplementary-material" rid="SF1">
<bold>Supplementary Information</bold>
</xref> was retrieved from LetPub (<ext-link ext-link-type="uri" xlink:href="http://www.letpub.com.cn">http://www.letpub.com.cn</ext-link>).</p>
</sec>
<sec id="s2_2">
<title>Statistical analysis</title>
<p>The retrieved data were exported in plain text format and subsequently imported into various tools for analysis and visualization, including Biblioshiny (a web interface based on Bibliometrix 4.3.3), VOSviewer (version 1.6.19), CiteSpace (version 6.4.R1), and Microsoft Excel (version 2021 Professional Edition). The processed files contained bibliographic metadata, including titles, publication dates, authors, countries/regions, affiliations, keywords, Keyword Plus, reference counts, cited references, abstracts, and other relevant information. The statistical analysis of this study is based on the comprehensive table (<xref ref-type="supplementary-material" rid="SF1">
<bold>Supplementary Table S1</bold>
</xref>).</p>
<p>Bibliometrix (<xref ref-type="bibr" rid="B11">11</xref>), an R-based bibliometric analysis and visualization package, was used for statistics and generating strategic maps. These two-dimensional maps position density (indicative of thematic development/maturity) on the vertical axis and centrality (reflecting a theme&#x2019;s connectivity and relevance to other themes) on the horizontal axis (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B13">13</xref>). National and author collaboration networks were analyzed using VOSviewer (<xref ref-type="bibr" rid="B14">14</xref>). A global distribution map of scientific output by country was created with SCImago Graphica (Beta version 1.0.49) (<xref ref-type="bibr" rid="B15">15</xref>). Cytoscape (<xref ref-type="bibr" rid="B16">16</xref>) (version 3.10.2) was employed to visualize author collaboration networks. CiteSpace (version 6.4.R1) (<xref ref-type="bibr" rid="B17">17</xref>) was employed to conduct a series of advanced bibliometric analyses, including keyword clustering, co-citation reference clustering, extraction of raw data for alluvial diagram construction, co-citation network analysis, and burst detection. Additionally, the software supports integration with the Ollama: llama3 8B model, thereby enhancing the efficiency and intelligence of bibliometric data processing. A modularity Q value greater than 0.3 and a mean silhouette score above 0.5 are generally considered to be indicative of robust and meaningful clustering results.</p>
<p>Visualization outputs, including pie charts, bubble plots, stacked bar charts, radar charts, histograms, line plots, violin plots and heatmaps, were generated using R (version 4.5.0). Statistical significance was determined using a p-value of less than 0.05.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<title>Results</title>
<sec id="s3_1">
<title>Overview of the study status</title>
<p>A total of 4,856 publications related to single-cell analysis in tumor immunotherapy were retrieved from WOSCC, including 4,481 original research articles and 375 review articles. These publications, spanning the years 1998 to 2025, were published across 736 academic journals. The dataset encompasses contributions from 37,912 authors, affiliated with 22,517 institutions in 66 countries. Country attribution was determined based on the institutional affiliations of all contributing authors.</p>
<p>
<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1A</bold>
</xref> shows the global distribution of publications. The top seven countries accounted for over 80% of the total number of articles. <xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1B</bold>
</xref> shows that the top seven countries with the highest publication counts were China (3,100), followed by the United States (1,290), Germany (244), the United Kingdom (189), Japan (150), South Africa (128), France (110) and the rest of the world (1169). <xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1C</bold>
</xref> shows the average citations per article and the total link strength for the top 10 most frequently cited countries. The top five countries by total citation count were the United States (74,989 citations), China (45,666), Germany (12,744), the United Kingdom (9,321), and Switzerland (8,261). Country attribution was determined using the full counting method as defined in VOSviewer for all author affiliations.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Global publishing overview. <bold>(A)</bold> Global distribution map of publication volume. <bold>(B)</bold> Top 7 countries by number of publications. <bold>(C)</bold> Top7 Countries with total citation. <bold>(D)</bold> Top 7 institutions ranked by total citations. <bold>(E)</bold> Annual trends in publication volume and citation frequency.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1640224-g001.tif">
<alt-text content-type="machine-generated">Map and charts illustrating global research collaboration and citations. Panel A shows a world map with countries color-coded by publication count. Panel B is a pie chart displaying the proportion of total publications from various countries, highlighting China and the USA. Panel C is a bubble chart comparing total citations and average article citations across countries, with bubble size representing total link strength. Panel D is another bubble chart showing leading institutions, with bubble size indicating the number of documents and color denoting average citations. Panel E is a radial plot of publications and citations over time from 1998 to 2025.</alt-text>
</graphic>
</fig>
<p>
<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1D</bold>
</xref> presents the top 10 institutions ranked by total citations, along with their average citations per article and the number of publications. The top 5 most cited institutions were Massachusetts General Hospital, Massachusetts Institute of Technology, Harvard Medical School, Peking University, and Dana-Farber/Brigham and Women&#x2019;s Cancer Center. Since 2017, the number of publications in this field has increased rapidly (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1E</bold>
</xref>). The volume of publications in this field is anticipated to increase steadily in the coming years.</p>
<p>
<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2A</bold>
</xref> shows that the number of authors per research article was significantly higher than that of review articles (<italic>P</italic> &lt; 0.0001). In contrast, <xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2B</bold>
</xref> demonstrates that review articles contained significantly more references than research articles (<italic>P</italic> &lt; 0.0001). A correlation analysis was subsequently performed after categorizing publications by their average annual citation frequency in <xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2C</bold>
</xref>. Articles with an average citation frequency greater than 10 were found to include significantly more references&#x2014;approximately 10 times the average&#x2014;than those with lower citation rates.</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Trends in the publication and citation of articles. <bold>(A)</bold> Comparison of the number of authors per article between research articles and reviews. <bold>(B)</bold> Comparison of the number of references per article between research articles and reviews. <bold>(C)</bold> Distribution of the number of references in articles grouped by different levels of annual average citations. <bold>(D)</bold> Temporal distribution of research articles and review papers across different publication periods. <bold>(E)</bold> Distribution of the number of research articles and review papers published by China, the United States, European Union and other countries. <bold>(F)</bold> Distribution of multiple-country publications (MCP) and single-country publications (SCP) for the top seven countries with the highest volume of SCP. MCP indicates international collaborations, whereas SCP reflects domestic collaborations only. *P &lt; 0.05, **P &lt; 0.01, ***P &lt; 0.001, ****P &lt; 0.0001.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1640224-g002.tif">
<alt-text content-type="machine-generated">The image contains multiple charts analyzing scientific documents. Chart A compares the number of authors in articles versus reviews, showing significant differences. Chart B compares the number of references in articles versus reviews, also indicating significant differences. Chart C analyzes the number of references based on annual average citations, with different citation ranges marked by significance levels. Chart D shows the number of documents over time, highlighting an increase in articles. Chart E compares document numbers by region, with China leading in articles. Chart F displays the MCP and SCP ratios for the top 7 countries in terms of publication volume.</alt-text>
</graphic>
</fig>
<p>An analysis of publication trends over time revealed that the number of research articles published before 2017 was relatively low, with a marked increase observed only after that year (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2D</bold>
</xref>). Moreover, the number of research articles consistently exceeded that of review articles across all time periods.</p>
<p>To avoid double counting, country attribution was determined by the affiliation of the first author. Given the political, economic, and cultural integration within the European Union, it was treated as a single entity for analytical purposes. Collectively, China and the United States, China and the European Union accounted for 88.8% of all publications,89.8% of research articles and 76.8% of reviews in the field. Furthermore, these three regions published 231.0% more review articles than all other countries combined (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2E</bold>
</xref>). Among European countries, the United Kingdom, France, and Germany demonstrated the highest levels of international collaboration, while the United States led in North America (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2F</bold>
</xref>). In contrast, China had the highest number of publications produced without international collaboration.</p>
</sec>
<sec id="s3_2">
<title>Author analysis</title>
<p>Given that first authors are often either corresponding authors or key contributors to a publication, we conducted a statistical analysis of first authors in this field using the bibliometrix R package. The h-index of each first author was calculated to assess their academic impact.</p>
<p>
<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3A</bold>
</xref> presents the h-indices of the top 10 first authors. Among them, Zhao Pengpeng (h = 7), Cheng Kai (h = 5), and Wang Zeyu (h = 4) exhibited the highest h-index values. As shown in <xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3B</bold>
</xref>, the authors with the highest number of publications as first authors were Zhang Pengpeng (9), Zhao Songyun (6), and Chen Kai (6). <xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3D</bold>
</xref> illustrates the annual publication output of the top 10 first authors, indicating that their relevant publications only began appearing after 2022. <xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3C</bold>
</xref> displays the top authors based on total citation frequency, with Patel Anoop P. (3,261), Tirosh Itay (2,956), and Newman Aaron M. (2,433) leading the list.</p>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Author analysis. <bold>(A)</bold> Top 10 first authors ranked by h-index. <bold>(B)</bold> Top 10 first authors with the highest number of publications. <bold>(C)</bold> Top 10 first authors with the highest total citation counts. <bold>(D)</bold> Annual publication trends of the top 10 most prolific first authors. <bold>(E)</bold> Co-authorship network of authors based on the top 200 standardized citation frequencies.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1640224-g003.tif">
<alt-text content-type="machine-generated">Five visualizations related to scholarly output. Panels A, B, and C are radar charts showing academic contributions by authors, with various names plotted around the edges. Panel D is a dot plot showing yearly output of first authors, from 2021 to 2025, with counts marked by color and size. Panel E is a network diagram displaying connections among authors, represented as nodes and lines, with some nodes prominently labeled.</alt-text>
</graphic>
</fig>
<p>It was observed that older publications generally accumulate more citations over time, whereas more recent works have had limited opportunity to do so. Moreover, citation patterns differ markedly across subfields, with certain research areas attracting significantly more scholarly attention. To reduce the confounding effects of publication year and disciplinary variation on citation frequency, a normalized citation metric was employed. Based on the top 200 authors, an author co-citation network was constructed to illustrate intellectual linkages within the field. In addition, an author collaboration network was visualized to identify key contributors. Notably, Zhang Pengpeng, Li Yang, and Wang Jie emerged as central figures in this network (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3E</bold>
</xref>). <xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref> presents detailed information on all aforementioned authors.</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Details of all authors listed, sorted alphabetically.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="center">Author</th>
<th valign="middle" align="center">Institution</th>
<th valign="middle" align="center">Country</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">Ammons Dylan T.</td>
<td valign="middle" align="left">Colorado State University</td>
<td valign="middle" align="left">United State</td>
</tr>
<tr>
<td valign="middle" align="left">Aoki Tomohiro</td>
<td valign="middle" align="left">British Columbia Cancer</td>
<td valign="middle" align="left">Canada</td>
</tr>
<tr>
<td valign="middle" align="left">Azizi Elham</td>
<td valign="middle" align="left">Memorial Sloan Kettering Cancer Center</td>
<td valign="middle" align="left">United State</td>
</tr>
<tr>
<td valign="middle" align="left">Benech Matthew G. K.</td>
<td valign="middle" align="left">Roswell Park Comprehensive Cancer Center Buffalo</td>
<td valign="middle" align="left">United State</td>
</tr>
<tr>
<td valign="middle" align="left">Chen Kai</td>
<td valign="middle" align="left">Peking University</td>
<td valign="middle" align="left">China</td>
</tr>
<tr>
<td valign="middle" align="left">Chen Lujun</td>
<td valign="middle" align="left">Third Affiliated Hospital of Soochow University</td>
<td valign="middle" align="left">China</td>
</tr>
<tr>
<td valign="middle" align="left">Chen Shuling</td>
<td valign="middle" align="left">Sun Yat-Sen University</td>
<td valign="middle" align="left">China</td>
</tr>
<tr>
<td valign="middle" align="left">Fu Jie</td>
<td valign="middle" align="left">Central South University</td>
<td valign="middle" align="left">China</td>
</tr>
<tr>
<td valign="middle" align="left">Helmink Beth A.</td>
<td valign="middle" align="left">The University of Texas Md Anderson Cancer Center</td>
<td valign="middle" align="left">United State</td>
</tr>
<tr>
<td valign="middle" align="left">Helmink Beth A.</td>
<td valign="middle" align="left">The University of Texas Md Anderson Cancer Center</td>
<td valign="middle" align="left">United State</td>
</tr>
<tr>
<td valign="middle" align="left">Newman Aaron M.</td>
<td valign="middle" align="left">Stanford University</td>
<td valign="middle" align="left">United State</td>
</tr>
<tr>
<td valign="middle" align="left">Patel Anoop P.</td>
<td valign="middle" align="left">Massachusetts General Hospital and Harvard Medical School</td>
<td valign="middle" align="left">United State</td>
</tr>
<tr>
<td valign="middle" align="left">Puram Sidharth V.</td>
<td valign="middle" align="left">Department Of Pathology and Center for Cancer Research</td>
<td valign="middle" align="left">United State</td>
</tr>
<tr>
<td valign="middle" align="left">Shen Kaiyu</td>
<td valign="middle" align="left">Zhejiang Chinese Medical University</td>
<td valign="middle" align="left">China</td>
</tr>
<tr>
<td valign="middle" align="left">Tirosh Itay</td>
<td valign="middle" align="left">Broad Institute of Mit and Harvard</td>
<td valign="middle" align="left">United State</td>
</tr>
<tr>
<td valign="middle" align="left">Wang Zeyu</td>
<td valign="middle" align="left">Central South University</td>
<td valign="middle" align="left">China</td>
</tr>
<tr>
<td valign="middle" align="left">Wei Jinfen</td>
<td valign="middle" align="left">South China University of Technology</td>
<td valign="middle" align="left">China</td>
</tr>
<tr>
<td valign="middle" align="left">Ye Bicheng</td>
<td valign="middle" align="left">Yangzhou Polytechnic College</td>
<td valign="middle" align="left">China</td>
</tr>
<tr>
<td valign="middle" align="left">Zhang Biao</td>
<td valign="middle" align="left">Dalian Medical University</td>
<td valign="middle" align="left">China</td>
</tr>
<tr>
<td valign="middle" align="left">Zhang Pengpeng</td>
<td valign="middle" align="left">Nanjing Medical University</td>
<td valign="middle" align="left">China</td>
</tr>
<tr>
<td valign="middle" align="left">Zhang Qi</td>
<td valign="middle" align="left">Zhejiang University</td>
<td valign="middle" align="left">China</td>
</tr>
<tr>
<td valign="middle" align="left">Zhang Yuanyuan</td>
<td valign="middle" align="left">Peking-Tsinghua Center for Life Sciences</td>
<td valign="middle" align="left">China</td>
</tr>
<tr>
<td valign="middle" align="left">Zhao Songyun</td>
<td valign="middle" align="left">Nanjing Medical University</td>
<td valign="middle" align="left">China</td>
</tr>
<tr>
<td valign="middle" align="left">Zheng Chunhong</td>
<td valign="middle" align="left">Peking University</td>
<td valign="middle" align="left">China</td>
</tr>
<tr>
<td valign="middle" align="left">Zilionis Rapolas</td>
<td valign="middle" align="left">Harvard Medical School</td>
<td valign="middle" align="left">United State</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s3_3">
<title>Country analysis</title>
<p>We conducted a comprehensive analysis of the countries affiliated with all authors, recording the institutional country information for each article. The results showed that China (12,836) and the United States (6,668) together accounted for 73.46% of all publications frequence (26,550) in this field, highlighting their dominant contribution. Subsequently, we analyzed the regional distribution of publications within China and the United States. <xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4A</bold>
</xref> illustrates the publication output across 32 regions of China, including Taiwan. The distribution is notably concentrated in coastal provinces, which aligns with the higher levels of economic development, better transportation infrastructure, resource availability, and regional clustering effects in these areas. Specifically, Shanghai (1,857), Guangdong (1,771), Jiangsu (1,184), and Zhejiang (777) ranked among the top contributors. In contrast, publication output from inland regions was relatively low. Apart from Beijing (1,287), research productivity across other regions was scattered and uneven, reflecting disparities in regional development and scientific capacity. <xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4B</bold>
</xref> shows the distribution of publications across 47 Unite States. The leading contributors were Massachusetts (1,121), California (931), New York (763), Texas (624), Maryland (409), Pennsylvania (366), Michigan (282), and Missouri (208). These states are characterized by strong economic foundations and a high concentration of scientific, technological, and educational resources, which likely contribute to their high publication output in this field.</p>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>Country-level analysis of publications. <bold>(A)</bold> Frequency distribution of publications by province in China. <bold>(B)</bold> Frequency distribution of publications by United states <bold>(C)</bold> Annual distribution of publications in China. <bold>(D)</bold> Annual distribution of publications in the United States. <bold>(E)</bold> Top 5 institutions in China by number of published research articles. <bold>(F)</bold> Top 5 institutions in China by number of published review articles. <bold>(G)</bold> Poll top 5 organizations with the most published articles in the US <bold>(H)</bold> Top 5 institutions in the United States by number of published review articles. <bold>(I)</bold> Comparison of the top 5 institutions in China and the United States by number of published articles. <bold>(J)</bold> Impact factor distribution of articles published in China and the United States. <bold>(K)</bold> Impact factor comparison of different publication types (research <italic>vs</italic>. review) in China and the United States. *P &lt; 0.05, **P &lt; 0.01, ***P &lt; 0.001, ****P &lt; 0.0001.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1640224-g004.tif">
<alt-text content-type="machine-generated">Map and bar charts analyze scientific publications from China and the U.S. Maps (A, B) show publication frequency by region. Bar charts (C, D) depict paper counts over time. Radar charts (E-H) display top universities for articles and reviews. Pie chart (I) shows publication shares among Chinese universities. Violin plots (J, K) compare impact factors by country and publication type.</alt-text>
</graphic>
</fig>
<p>Given the variability in the number of authors per article, countries with larger author lists may be overrepresented in publication frequency statistics. To mitigate this bias, we analyzed publications based on the country and institutional affiliation of the first author. Since authors often report multiple affiliations, we considered only the first-listed institution, as it typically reflects the primary workplace and main research output source of the author. In the field of single-cell research and immunotherapy, first authors were affiliated with institutions across 57 countries. Notably, China and the United States together accounted for 3,920 publications, representing 80.72% of the global output (n = 4,856). Given their dominant contribution, we conducted a more detailed analysis of first-author affiliations within these two countries.</p>
<p>Since only one article with a first author from China was published before 2017 (in 2009), we plotted the annual publication trend starting from 2017 and performed a curve fitting analysis (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4C</bold>
</xref>). The results show a steady increase in China&#x2019;s publication output from 2017 onward, with a sharp surge beginning in 2020. The number of publications peaked in 2024, reflecting a remarkable growth rate of 283.2%. This rapid expansion indicates substantial progress in scientific research and collaboration within China, underscoring the country&#x2019;s increasing impact on global academic output. Continued growth is anticipated in the coming years.</p>
<p>In contrast, the United States began to exhibit an increasing publication trend earlier, with a noticeable rise starting after 2012. Therefore, we analyzed and fitted the annual publication trend of U.S. first authors from 2012 onward (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4D</bold>
</xref>). Between 2012 and 2015, publication growth was relatively modest, followed by a significant acceleration beginning in 2016, with an annual growth rate reaching 25.12%. This upward trajectory is expected to persist. Prior to 2012, there were only three relevant publications from first authors in the United States&#x2014;one each in 2002, 2005, and 2008.</p>
<p>Subsequently a statistical analysis of the publication frequency of institutions affiliated with first authors in China and the United States was conducted. <xref ref-type="fig" rid="f4">
<bold>Figures&#xa0;4E&#x2013;H</bold>
</xref> present the top 5 institutions for original research articles and reviews in each country: Chinese research articles (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4E</bold>
</xref>), Chinese reviews (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4F</bold>
</xref>), U.S. research articles (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4G</bold>
</xref>), and U.S. reviews (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4H</bold>
</xref>).</p>
<p>In China, the most prolific institutions were Fudan University (articles: 149; reviews: 9), Sun Yat-sen University (articles: 142; reviews: 3), and Shanghai Jiao Tong University (articles: 116; reviews: 9). In the United States, leading contributors included Dana-Farber Cancer Institute (articles: 27; reviews: 5), the National Cancer Institute (NCI) (articles: 21; reviews: 5), and Washington University (articles: 21; reviews: 4). Collectively, the top 5 institutions from China and the United States accounted for 15.10% of all publications originating from these two countries.</p>
<p>
<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4I</bold>
</xref> summarizes the overall top 5 institutions across both countries. Among them, Fudan University, Sun Yat-sen University, and Shanghai Jiao Tong University ranked as the top 3 contributors, highlighting China&#x2019;s strong institutional presence in this field.</p>
<p>Afterwards the impact factors of articles published in China and the United States were analyzed. JCR&#x2019;s latest impact factors for 2023 were used. The impact factors of journals not included in the latest JCR journals SCIE are recorded as 0. The number of articles in China is 32, while the number of articles in the United States is 21. There are 19 magazines that are not included. It was found that the impact factor of USA articles (n = 922) was substantially greater than that of Chinese articles (n = 2998) (p &lt; 0.0001) (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4J</bold>
</xref>). In order to further clarify, an analysis chart of the impact factors of Chinese and American articles and reviews was displayed in <xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4H</bold>
</xref> and found that American articles had significantly higher impact factors than those of Chinese articles (p &lt; 0.0001) and reviews (p &lt; 0.0001). The impact factor of the USA review was significantly higher than that of the Chinese article (p &lt; 0.0001) and the review (p &lt; 0.05). This may be related to the large number of articles published in China, including many articles with low impact factors. There were no significant differences in the impact factors between USA articles and reviews. At the same time, there were no significant differences in the impact factors between Chinese articles and reviews.</p>
<p>Given the close collaboration among the European Union member states, the European Union in many aspects functions similarly to a federal state. Therefore, we treated the European Union as a single entity in our analysis. A publication threshold of six documents was applied to define active countries, resulting in the inclusion of the top 21 most productive countries for the interaction network analysis (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5A</bold>
</xref>).</p>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>Comparative Analysis of China, the United States, and the European Union. <bold>(A)</bold> Interaction network analysis among the top 21 contributing countries, with the European Union treated as a single entity. Each node represents a country, with node size proportional to its total citation count. Node colors indicate different clusters or collaboration groups. The thickness of the connecting lines reflects the strength of international collaboration&#x2014;thicker lines represent stronger collaborative ties. <bold>(B)</bold> Comparison of the top 100 most-cited publications from China, the United States, and the European Union. <bold>(C)</bold> Comparative evaluation of the impact factors of the top 100 publications from China, the United States, and the European Union. *P &lt; 0.05, **P &lt; 0.01, ***P &lt; 0.001, ****P &lt; 0.0001.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1640224-g005.tif">
<alt-text content-type="machine-generated">Diagram of international citation analysis. Panel A shows a network diagram of publication flows among countries, visualized in three clusters. Panel B displays a violin plot of total citations for the United States, European Union, and China, with significant differences marked. Panel C presents a violin plot of impact factors for the same regions.</alt-text>
</graphic>
</fig>
<p>The interaction map revealed that these top 21 countries could be grouped into three major clusters based on collaboration strength: Cluster 1: Led by the United States, the European Union, and the United Kingdom; Cluster 2: Led by China and Singapore; Cluster 3: Led by Japan and India. Notably, the lines connecting the United States, the European Union, and China were the thickest in the network, indicating the strongest international collaborations among them. Notably, the lines connecting the United States, the European Union, and China were the thickest in the network, indicating the strongest international collaborations among them.</p>
<p>A comparative analysis of total publication volume and citation performance (<xref ref-type="supplementary-material" rid="SF2">
<bold>Supplementary Figure S1</bold>
</xref>) showed that the United States (total citations: 74,989; normalized citations: 1,843.5), the European Union (37,486; 1,026.8), and China (45,666; 2,703.7) were the top 3 most influential contributors in the field. Although the European Union produced only 685 publications, its total citation count reached 37,486, resulting in an average citation per article of 54.7&#x2014;lower than that of the United States (58.1) but significantly higher than China (14.7).</p>
<p>To further evaluate their academic influence, we analyzed the top 100 most-cited publications from the United States, China, and the European Union, based on the affiliation of the first author (see <xref ref-type="supplementary-material" rid="SF1">
<bold>Supplementary Table S2</bold>
</xref>). The composition of these top-cited papers varied slightly: the United States contributed 92 original research articles and 8 reviews; China contributed 87 articles and 13 reviews; and the European Union contributed 79 articles and 21 reviews. The analysis revealed that the United States had significantly higher citation counts for its top 100 papers compared to the European Union (<italic>P</italic> &lt; 0.0001) and China (<italic>P</italic> &lt; 0.001) (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5B</bold>
</xref>). Similarly, the impact factors of the journals in which these top papers were published were also significantly higher for the United States than for the European Union (<italic>P</italic> &lt; 0.0001) and China (<italic>P</italic> &lt; 0.001) (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5C</bold>
</xref>).</p>
</sec>
<sec id="s3_4">
<title>Literature analysis</title>
<p>
<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6A</bold>
</xref> presents the global top 10 most cited articles in this field. To control for the effects of publication year and journal subject category, both raw impact factors and normalized citation frequencies were included. As shown, the article by Patel et&#xa0;al. (2014, <italic>Science</italic>) received the highest total citation count. This landmark study pioneered single-cell sequencing in the context of tumor heterogeneity, revealing substantial transcriptional differences between individual cells within the same tumor and even within different bowel regions of the same patient (<xref ref-type="bibr" rid="B18">18</xref>). These findings underscore the critical need to account for intratumoral heterogeneity in the design of effective immunotherapies.</p>
<fig id="f6" position="float">
<label>Figure&#xa0;6</label>
<caption>
<p>literature analysis. <bold>(A)</bold> Top 10 most globally cited publications. <bold>(B)</bold> Top 10 most locally cited publications. <bold>(C)</bold> Alluvial flow map of representative literature. <bold>(D)</bold> Literature co-citation analysis network. <bold>(E)</bold> Cluster analysis of co-cited literature. <bold>(F)</bold> Burst detection analysis of highly influential literature ranked by starting year.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1640224-g006.tif">
<alt-text content-type="machine-generated">A composite image featuring multiple panels depicting citation analyses of scientific documents. Panels A and B are bubble charts showing total and local citations of various documents, with bubble size and color representing normalized citations and impact factor. Panel C is a trend line graph connecting citations over time from 2017 to 2024, highlighting specific documents. Panel D displays a network graph of co-citation relationships and line graphs showing citation counts from 2018 to 2025 for selected documents. Panel E is a modularity network diagram illustrating clusters of documents. Panel F is a tabular summary of references with strength, timeframe, and a bar chart.</alt-text>
</graphic>
</fig>
<p>The review by De Visser et&#xa0;al. (2023, <italic>Cancer Cell</italic>) ranked highest in terms of journal impact factor and standardized citation frequency. This article provides comprehensive insights into the role of TME in cancer progression, emphasizing its dynamic and evolving nature as a determinant of tumor behavior (<xref ref-type="bibr" rid="B19">19</xref>).</p>
<p>
<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6B</bold>
</xref> highlights the top 10 most locally cited articles&#x2014;those with the highest citation frequencies within the analyzed dataset. Among them, the study by Tirosh et&#xa0;al. (2016, <italic>Science</italic>) had the highest local citation count, representing the first systematic single-cell-level characterization of the multicellular ecosystem in malignant melanoma (<xref ref-type="bibr" rid="B20">20</xref>). Zhang et&#xa0;al. (2020, <italic>Cell</italic>) (<xref ref-type="bibr" rid="B21">21</xref>) achieved the highest normalized citation frequency, while Guo et&#xa0;al. (2018, <italic>Nature Medicine</italic>) (<xref ref-type="bibr" rid="B22">22</xref>) was published in the journal with the highest impact factor among the top local citations.</p>
<p>To avoid underestimating emerging high-impact studies that may not have yet accumulated sufficient citations due to their recent publication dates, we applied normalized citations as a screening criterion. Specifically, we identified the top 10 documents based on local normalized citation frequency and the top 10 based on global normalized citation frequency (<xref ref-type="table" rid="T2">
<bold>Table&#xa0;2</bold>
</xref>). Notably, the majority of these papers were published after 2022, highlighting the growing influence of recent research in this field.</p>
<table-wrap id="T2" position="float">
<label>Table&#xa0;2</label>
<caption>
<p>Top 10 documents ranked by normalized citation impact.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="center">Rank</th>
<th valign="middle" align="center">Document</th>
<th valign="middle" align="center">Normalized Local Citations</th>
<th valign="middle" align="center">Document</th>
<th valign="middle" align="center">Normalized Global Citations</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">1</td>
<td valign="middle" align="left">YE BC, 2025, BIOFACTORS</td>
<td valign="middle" align="left">142.00</td>
<td valign="middle" align="left">
<bold>DE VISSER KE, 2023, CANCER CELL</bold>
</td>
<td valign="middle" align="left">90.87</td>
</tr>
<tr>
<td valign="middle" align="left">2</td>
<td valign="middle" align="left">LI PH, 2025, CURR MED CHEM</td>
<td valign="middle" align="left">142.00</td>
<td valign="middle" align="left">HE SY, 2025, NAT BIOTECHNOL</td>
<td valign="middle" align="left">81.14</td>
</tr>
<tr>
<td valign="middle" align="left">3</td>
<td valign="middle" align="left">ZHANG YY, 2025, CANCER CELL</td>
<td valign="middle" align="left">142.00</td>
<td valign="middle" align="left">SUN YF, 2025, HEPATOLOGY</td>
<td valign="middle" align="left">50.71</td>
</tr>
<tr>
<td valign="middle" align="left">4</td>
<td valign="middle" align="left">LIN ZH, 2024, FRONT IMMUNOL</td>
<td valign="middle" align="left">55.65</td>
<td valign="middle" align="left">LAMARCHE NM, 2024, NATURE</td>
<td valign="middle" align="left">21.89</td>
</tr>
<tr>
<td valign="middle" align="left">5</td>
<td valign="middle" align="left">XING J, 2024, FRONT IMMUNOL</td>
<td valign="middle" align="left">48.23</td>
<td valign="middle" align="left">YU YF, 2025, INT J SURG</td>
<td valign="middle" align="left">20.29</td>
</tr>
<tr>
<td valign="middle" align="left">6</td>
<td valign="middle" align="left">
<bold>DE VISSER KE, 2023, CANCER CELL</bold>
</td>
<td valign="middle" align="left">47.42</td>
<td valign="middle" align="left">WU YC, 2022, CANCER DISCOV</td>
<td valign="middle" align="left">19.57</td>
</tr>
<tr>
<td valign="middle" align="left">7</td>
<td valign="middle" align="left">SHAO WW, 2024, FRONT IMMUNOL</td>
<td valign="middle" align="left">44.52</td>
<td valign="middle" align="left">
<bold>LIU Y, 2023, J HEPATOL</bold>
</td>
<td valign="middle" align="left">19.48</td>
</tr>
<tr>
<td valign="middle" align="left">8</td>
<td valign="middle" align="left">
<bold>LIU Y, 2023, J HEPATOL</bold>
</td>
<td valign="middle" align="left">43.24</td>
<td valign="middle" align="left">MA P, 2024, CIRCULATION</td>
<td valign="middle" align="left">18.55</td>
</tr>
<tr>
<td valign="middle" align="left">9</td>
<td valign="middle" align="left">
<bold>MA JQ, 2024, SCIENCE</bold>
</td>
<td valign="middle" align="left">40.81</td>
<td valign="middle" align="left">
<bold>MA JQ, 2024, SCIENCE</bold>
</td>
<td valign="middle" align="left">17.44</td>
</tr>
<tr>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">WU YC, 2022, CANCER DISCOV</td>
<td valign="middle" align="left">38.05</td>
<td valign="middle" align="left">YARCHOAN M, 2024, NAT MED</td>
<td valign="middle" align="left">16.69</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>
<sup>#</sup>Publications marked in bold are shared across both lists.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Our analysis revealed distinct thematic focuses between the local and global top 10 papers. The local top 10 papers predominantly concentrate on single-cell atlases of cancer [local top 1 (<xref ref-type="bibr" rid="B23">23</xref>), 3 (<xref ref-type="bibr" rid="B24">24</xref>), 4 (<xref ref-type="bibr" rid="B25">25</xref>), 5 (<xref ref-type="bibr" rid="B26">26</xref>), 7 (<xref ref-type="bibr" rid="B27">27</xref>)] and immune cell populations [local top 2 (<xref ref-type="bibr" rid="B28">28</xref>), 5, 8 (<xref ref-type="bibr" rid="B29">29</xref>), 9 (<xref ref-type="bibr" rid="B30">30</xref>), 10 (<xref ref-type="bibr" rid="B31">31</xref>)]. In contrast, the global top 10 papers place greater emphasis on predictive models [global top 2 (<xref ref-type="bibr" rid="B32">32</xref>), 5 (<xref ref-type="bibr" rid="B33">33</xref>)] and clinical applications [global top 10 (<xref ref-type="bibr" rid="B34">34</xref>)]. Of particular note, the shared local top 6 and top 8 publications provide in-depth insights into the TME (<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B29">29</xref>), while the shared top 9 paper presents a comprehensive cross-cancer atlas of B-cell populations (<xref ref-type="bibr" rid="B30">30</xref>).</p>
<p>Subsequently, we analyzed the top 10% of most frequently cited references from 1998 to 2025 using CiteSpace (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6C</bold>
</xref>), limiting the maximum number of selected references to no more than 100 per year. The resulting annual networks were then imported into the Alluvial Generator (<ext-link ext-link-type="uri" xlink:href="https://www.mapequation.org/apps/MapGenerator.html">https://www.mapequation.org/apps/MapGenerator.html</ext-link>) for visualization of citation flow and temporal evolution. For network modeling, a six-link strength threshold and a six-year backtracking window were applied for each node to trace persistent citation trajectories. The analysis revealed that citation flows lasting more than six years were predominantly concentrated between 2017 and 2024, indicating a sustained and intensifying scholarly focus during this period.</p>
<p>
<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6C</bold>
</xref> highlights several pivotal cross-linking nodes situated at the intersection of major citation flows, suggesting their central role in shaping the field. Notable examples include <italic>Lambrechts D., 2018, Nature Medicine</italic> (<xref ref-type="bibr" rid="B35">35</xref>); <italic>Sade-Feldman M., 2018, Cell</italic> (<xref ref-type="bibr" rid="B36">36</xref>); and <italic>Guo X.Y., 2018, Nature Medicine</italic> (<xref ref-type="bibr" rid="B22">22</xref>)&#x2014;all of which represent foundational contributions to the development of single-cell and immunotherapy research.</p>
<p>Furthermore, a co-citation analysis was performed on the top 10% most-cited references from 2017 to 2025, with a maximum of 100 references included per year (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6D</bold>
</xref>). The analysis identified two key publications&#x2014;referred to as Article 1 and Article 2&#x2014;with notably high betweenness centrality, indicating their pivotal role in connecting different research clusters within the field. The temporal trends in their local citation frequencies are illustrated in the accompanying inset graphs. Article 1, <italic>Cheng S.J., 2021, Cell</italic>, has steadily gained attention for its comprehensive exploration of the composition and functional heterogeneity of tumor-infiltrating myeloid cells across various cancer types. The study underscores the importance of accounting for intertumoral differences in myeloid cell profiles when designing targeted immunotherapeutic strategies (<xref ref-type="bibr" rid="B7">7</xref>). Article 2, <italic>Zheng G.X.Y., 2017, Nature Communications</italic>, exhibited a burst strength of 21.6816 and began to attract widespread interest starting in 2018, with sustained influence through 2022. This study introduces a high-throughput single-cell RNA sequencing platform based on microdroplet technology&#x2014;namely, 10x Genomics&#x2019; GemCode system. This technological breakthrough represents a significant milestone in scalable single-cell transcriptomic profiling. Its application has not only advanced our understanding of the tumor immune microenvironment but also laid a critical foundation for the development of novel immunotherapeutic approaches (<xref ref-type="bibr" rid="B37">37</xref>).</p>
<p>To further explore the intellectual structure of single-cell research in immunotherapy from 1998 to 2025, a co-citation analysis was conducted using the g-index algorithm (k = 25) to identify highly influential references. To delineate the longitudinal evolution of research themes, a clustering analysis was performed based on article titles as indexing terms. Cluster formation and thematic labeling were carried out using a combination of the llama3 8B language model, Latent Log-Likelihood Ratio (LLR), and Semantic Indexing (LSI) methods (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6E</bold>
</xref>). The detailed naming and characteristics of each cluster are provided in <xref ref-type="supplementary-material" rid="SF4">
<bold>Supplementary Table S3</bold>
</xref>.</p>
<p>As shown in <xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6E</bold>
</xref>, cluster 0 appears to represent an emergent and evolving core theme within the field, likely originating from clusters 2, 3, 4, 8, 9, 11, 14, and 19&#x2014;indicating a convergent trajectory in research focus. Cluster 0 is characterized by studies centered on the tumor immune microenvironment, a key concept in understanding immunotherapeutic mechanisms at the single-cell level. Representative publications within this cluster include seminal works such as Tirosh et&#xa0;al. (2016, <italic>Science</italic>) (<xref ref-type="bibr" rid="B20">20</xref>), which introduced single-cell transcriptomic profiling in melanoma; Newman et&#xa0;al. (2019, <italic>Nature Biotechnology</italic>) (<xref ref-type="bibr" rid="B38">38</xref>), who developed CIBERSORTx for cell-type deconvolution; Helmink et&#xa0;al. (2020, <italic>Nature</italic>) (<xref ref-type="bibr" rid="B39">39</xref>), which investigated tertiary lymphoid structures and immunotherapy response; and Puram et&#xa0;al. (2017, <italic>Cell</italic>) (<xref ref-type="bibr" rid="B40">40</xref>), which mapped head and neck squamous cell carcinoma at single-cell resolution.</p>
<p>The originating clusters that feed into #0 reflect a diverse but interconnected research landscape: Mass Cytometry (#2), Tumor Immune Signatures (#3), Cancer Immune Dynamics (#4), Immunotherapy Response Prediction (#8), Precision Medicine (#9), High-Throughput Single-Cell Microtechnologies (#10), T Cell Dysfunction (#11), Functional Proteomics (#14) and Cancer Immune Cell Dynamics (#19).</p>
<p>This thematic convergence underscores the increasing integration of high-dimensional single-cell technologies, computational modeling, and systems immunology to decode the spatial, phenotypic, and functional complexity of the tumor-immune interface.</p>
<p>Subsequently, the top 10 references with the strongest citation bursts were identified and visualized in <xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6F</bold>
</xref>. Among these, <italic>Tirosh I, 2016, Science</italic> (<xref ref-type="bibr" rid="B20">20</xref>) exhibited the highest burst intensity (strength = 73.47), with sustained high attention from 2017 to 2021. This pivotal study leveraged single-cell transcriptomic techniques to dissect the cellular composition and functional states within metastatic melanoma, highlighting the profound complexity of the tumor and its microenvironment. Following closely is <italic>Zheng C.H., 2017, Cell</italic>, which demonstrated a burst strength of 55.82. This study utilized single-cell transcriptomic analysis to reveal the heterogeneity of dendritic cells and monocytes in human peripheral blood, leading to the identification of novel immune cell subsets (<xref ref-type="bibr" rid="B6">6</xref>). These findings have opened new avenues for understanding immune system dynamics and designing immunotherapeutic strategies.</p>
</sec>
<sec id="s3_5">
<title>Keyword analysis</title>
<p>To capture a broader range of keywords, the g-index algorithm (k = 25) in CiteSpace was utilized (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7A</bold>
</xref>). After exporting the.net file, the data were imported into the MapEquation platform (<ext-link ext-link-type="uri" xlink:href="https://www.mapequation.org/apps/MapGenerator.html">https://www.mapequation.org/apps/MapGenerator.html</ext-link>) to generate an impact flow diagram. For network modeling, each node was assigned six of its strongest connections, and a backtracking window of six years was applied. The analysis identified three persistent thematic streams, each extending for more than six years and concentrated within the period from 2017 to 2024&#x2014;consistent with the temporal pattern observed in the reference citation flow. Representative keywords in these streams are annotated in the figure. Notably, cross-cutting terms such as &#x201c;acquired resistance&#x201d; and &#x201c;expression&#x201d; suggest that researchers have maintained long-term interest in understanding resistance mechanisms and gene expression dynamics in the context of single-cell analysis of cancer immunotherapy. Based on the dominant keywords within the three major streams, the long-standing research foci since 2017 can be broadly categorized into the following areas: Heterogeneity and differentiation of resistant tumor cells &#x2013; represented by keywords such as <italic>diversity</italic> and <italic>differentiation</italic>, highlighting the evolving landscape of tumor cell plasticity under therapeutic pressure; Immune resistance induced by antibody-based therapies &#x2013; mediated by <italic>macrophages</italic> and <italic>antibodies</italic>, reflecting research on how therapeutic antibodies can unintentionally drive immune cell dysfunction or tolerance; Immune cell exhaustion and memory impairment &#x2013; exemplified by terms such as <italic>acute lymphoblastic leukemia</italic>, <italic>memory</italic>, <italic>Epstein-Barr virus</italic>, and <italic>exhaustion</italic>. This reflects interest in T cell exhaustion, wherein chronic antigen exposure and inflammation impair effector functions and memory formation, particularly in cancer and persistent viral infections.</p>
<fig id="f7" position="float">
<label>Figure&#xa0;7</label>
<caption>
<p>Keyword analysis. <bold>(A)</bold> Alluvial flow map of keywords. <bold>(B)</bold> Cluster analysis based on keyword co-occurrence. <bold>(C)</bold> Word cloud of author keywords in research articles. <bold>(D)</bold> Word cloud of author keywords in review articles. <bold>(E)</bold> Heatmap of the top 20 most frequent author keywords. <bold>(F)</bold> Strategic diagram (strategic coordinate map) of keyword clusters.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1640224-g007.tif">
<alt-text content-type="machine-generated">Infographic analyzing trends in cancer research. Panel A displays a Sankey diagram showing topic connections from 2017 to 2024. Panel B presents clusters with modularity and silhouette scores. Panel C is a word cloud of common article terms, highlighting &#x201c;prognosis&#x201d; and &#x201c;hepatocellular carcinoma.&#x201d; Panel D features a word cloud for reviews, emphasizing &#x201c;immunotherapy.&#x201d; Panel E contains a heat map of keyword distribution over time. Panel F charts themes based on development and relevance degrees, categorizing them into Niche and Basic Themes.</alt-text>
</graphic>
</fig>
<p>Furthermore, a keyword co-occurrence clustering analysis was performed using CiteSpace (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7B</bold>
</xref>), yielding a modularity value of Q = 0.3229 and a silhouette score of S = 0.6635, indicative of a moderately robust and internally consistent clustering structure. Cluster labeling was facilitated through integration of the llama 3B language model, in combination with LLR and LSI algorithms to improve thematic interpretability. Detailed cluster descriptors and characteristics are provided in <xref ref-type="supplementary-material" rid="SF5">
<bold>Supplementary Table S4</bold>
</xref>. The analysis identified several major thematic domains within the field, with the largest and most central cluster labeled as #0: Cancer Microenvironment Dynamics. Other prominent clusters include: #1 Single-Cell Analysis; #2 Tumor; Microenvironment; #3 Disease Diagnosis Tools; #4 Immune Cell Dynamics; #5 Tumor Microenvironment Analysis; #6 Machine Learning; #7 Receptor; #8 Cancer Immunotherapy.</p>
<p>To further investigate research hotspots, articles (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7C</bold>
</xref>) and reviews (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7D</bold>
</xref>) were analyzed separately using word cloud analysis based on authors&#x2019; keywords. For articles, the most frequently occurring bioinformatics-related keywords included: <italic>single-cell RNA sequencing</italic> (836), <italic>machine learning</italic> (142), <italic>single-cell analysis</italic> (118), <italic>single-cell sequencing</italic> (94), <italic>prognostic model</italic> (87), <italic>bioinformatics</italic> (77), <italic>spatial transcriptomics</italic> (47), and <italic>multi-omics</italic> (42). The most commonly studied cancer types were: <italic>hepatocellular carcinoma</italic> (208), <italic>colorectal cancer</italic> (141), <italic>breast cancer</italic> (121), <italic>lung adenocarcinoma</italic> (121), <italic>gastric cancer</italic> (108), <italic>pancreatic cancer</italic> (68), <italic>glioblastoma</italic> (64), <italic>melanoma</italic> (57), <italic>bladder cancer</italic> (56), <italic>osteosarcoma</italic> (54), <italic>pan-cancer</italic> (54), <italic>ovarian cancer</italic> (53), <italic>prostate cancer</italic> (46), <italic>squamous cell carcinoma</italic> (45), and <italic>triple-negative breast cancer</italic> (36).</p>
<p>In terms of cancer treatment and immune-related research, frequently cited terms included: <italic>tumor microenvironment</italic> (618), <italic>immunotherapy</italic> (600), <italic>prognosis</italic> (470), <italic>immune infiltration</italic> (155), <italic>immune microenvironment</italic> (127), <italic>tumor immune microenvironment</italic> (125), <italic>biomarker</italic> (144), <italic>macrophage</italic> (90), <italic>prognostic signature</italic> (78), <italic>heterogeneity</italic> (64), <italic>cancer-associated fibroblasts</italic> (52), <italic>tumor-associated macrophages</italic> (41), <italic>tumor heterogeneity</italic> (39), <italic>drug sensitivity</italic> (38), <italic>ferroptosis</italic> (37), <italic>immune checkpoint</italic> (37), and <italic>immune checkpoint inhibitors</italic> (36).</p>
<p>For reviews, the keyword frequency was generally lower, but several specific themes emerged. Frequently mentioned bioinformatics-related terms included <italic>deep learning</italic> (5) and <italic>mass cytometry</italic> (9). Keywords related to cancer treatment and immunological mechanisms included: <italic>heterogeneity</italic> (18), <italic>tumor heterogeneity</italic> (17), <italic>precision medicine</italic> (10), <italic>drug resistance</italic> (8), <italic>angiogenesis</italic> (6), <italic>immune-related adverse events</italic> (4), and <italic>immune landscape</italic> (4).</p>
<p>These findings reflect a growing emphasis on computational methods, immune interactions, and tumor heterogeneity in both original research and comprehensive reviews within the field of single-cell immunotherapy.</p>
<p>To further illustrate the temporal evolution and emerging trends of research topics, a heatmap analysis was conducted based on the annual frequency of the top 20 author keywords (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7E</bold>
</xref>). The results show that keywords such as <italic>machine learning</italic>, <italic>prognostic model</italic>, <italic>immune microenvironment</italic>, and heterogeneity have demonstrated a clear upward trend in recent years, suggesting that these topics are gaining increasing attention and are likely to remain focal points in future research. Keyword relevance analysis revealed that the tumor immune microenvironment is positively associated with tumors, while the tumor microenvironment shows a positive correlation with spatial transcriptomics. (<xref ref-type="supplementary-material" rid="SF6">
<bold>Supplementary Figure S2</bold>
</xref>).</p>
<p>To evaluate the developmental stage and research maturity of various topics in the field of single-cell immunotherapy, a thematic strategic diagram was constructed (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7F</bold>
</xref>). This strategic coordinate plot categorizes topics based on centrality (representing importance and connectivity to other themes) and density (indicating the degree of internal development).</p>
<p>Core foundational topics such as <italic>single-cell RNA sequencing</italic>, <italic>single-cell analysis</italic>, and <italic>tumor immune microenvironment</italic> occupy the lower-right quadrant, indicating high centrality but relatively low density&#x2014;suggesting they are well-established and broadly connected to other topics but still offer significant potential for further in-depth exploration.</p>
<p>Topics such as <italic>immunotherapy</italic>, <italic>tumor microenvironment</italic>, and <italic>macrophage</italic> appear in the upper-middle quadrant. These themes possess relatively high centrality and moderate density, indicating they serve as hubs that connect multiple research directions and have already undergone considerable investigation. However, their moderate internal cohesion also highlights the opportunity for further refinement and specialization.</p>
<p>Collectively, these topics form the core framework of &#x201c;broadly connected and expandable&#x201d; research within the field and represent valuable entry points for deepening and integrating future interdisciplinary efforts.</p>
</sec>
<sec id="s3_6">
<title>Journal analysis</title>
<p>A bubble chart was generated to visualize the top 10 most-cited journals, illustrating their total citation counts, number of publications, average citations per article, and impact factors (<xref ref-type="fig" rid="f8">
<bold>Figure&#xa0;8A</bold>
</xref>). The top 5 most frequently cited journals are <italic>Cell</italic> (13491), <italic>Nature Communications</italic> (9482), <italic>Science</italic> (7272), <italic>Nature</italic> (6130), and <italic>Frontiers in Immunology</italic> (5713). Among them, <italic>Science</italic> exhibits the highest average citation per article (1038.9), followed by <italic>Cell</italic> (465.2). In terms of impact factor, <italic>Nature Medicine</italic> (58.7) ranks first, followed by <italic>Nature</italic> (50.5).</p>
<fig id="f8" position="float">
<label>Figure&#xa0;8</label>
<caption>
<p>Journal analysis. <bold>(A)</bold> Top 10 journals ranked by total citation count. <bold>(B)</bold> A Top 10 journals ranked by number of publications. <bold>(C)</bold> Annual publication trends of the top 10 journals. <bold>(D)</bold> Dual-map overlay of journal citation relationships. <bold>(E)</bold> Distribution of total citations across different journal impact factor ranges. <bold>(F)</bold> Impact factor comparison across different article types. <bold>(G)</bold> Distribution of journal impact factors across different publication years. *P &lt; 0.05, **P &lt; 0.01, ***P &lt; 0.001, ****P &lt; 0.0001.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1640224-g008.tif">
<alt-text content-type="machine-generated">Panel A shows a bubble chart of total citations for various journals, with size indicating average citations and color indicating impact factor. Panel B displays a similar chart for publication count. Panel C uses bar charts to show the number of publications per journal. Panel D features a citation network diagram from 2015 to 2025, connecting disciplines like molecular biology and medicine. Panel E contains a violin plot relating total citations to impact factor. Panel F compares impact factors between articles and reviews. Panel G presents a violin plot of impact factors across different years.</alt-text>
</graphic>
</fig>
<p>Subsequently, a bubble chart of the top 10 journals with the highest number of publications was constructed (<xref ref-type="fig" rid="f8">
<bold>Figure&#xa0;8B</bold>
</xref>). The leading three journals in terms of publication volume are <italic>Frontiers in Immunology</italic> (410), <italic>Nature Communications</italic> (150), and <italic>Journal for Immunotherapy of Cancer</italic> (138). <italic>Nature Communications</italic> (14.7) ranks highest in both total citation frequency and impact factor, followed closely by <italic>Frontiers in Immunology</italic> (5.7).</p>
<p>Further temporal analysis based on publication year (<xref ref-type="fig" rid="f8">
<bold>Figure&#xa0;8C</bold>
</xref>) revealed that the peak period of publication activity occurred between 2022 and 2024. <italic>Frontiers in Immunology</italic> maintained the highest annual publication volume throughout this period, followed by <italic>Nature Communications</italic>.</p>
<p>The superposition of dual-map overlays was used to illustrate the knowledge flow paths (<xref ref-type="fig" rid="f8">
<bold>Figure&#xa0;8D</bold>
</xref>). As shown in the figure, research from the molecular, biological, and genomics fields, along with health and medical sciences, converges into the molecular, biological, and immunological disciplines. Furthermore, molecular, biological, and genomic studies have extended into clinical, pharmaceutical, and medical fields.</p>
<p>To explore the relationship between journal impact factors and citation frequency, impact factors were divided into four categories: 0&#x2013;5, 5&#x2013;10, 10&#x2013;20, and &gt;20. As shown in <xref ref-type="fig" rid="f8">
<bold>Figure&#xa0;8E</bold>
</xref>, articles published in journals with an impact factor greater than 20 had significantly higher citation frequencies compared to those in the 10&#x2013;20 range (p &lt; 0.0001). Similarly, articles in the 10&#x2013;20 impact factor range were cited more frequently than those in the 5&#x2013;10 range (p &lt; 0.0001), and articles in the 5&#x2013;10 range had higher citation frequencies than those with impact factors between 0&#x2013;5 (p &lt; 0.0001).</p>
<p>Differences in impact factors between original research articles and review articles were also assessed (<xref ref-type="fig" rid="f8">
<bold>Figure&#xa0;8F</bold>
</xref>), revealing no statistically significant difference. Additionally, the temporal distribution of impact factors was analyzed (<xref ref-type="fig" rid="f8">
<bold>Figure&#xa0;8G</bold>
</xref>). Publications from 2017 to 2020 had significantly higher impact factors than those from 1998 to 2016 (p = 0.01). Furthermore, impact factors in 2021&#x2013;2022 were significantly greater than those in 2017&#x2013;2020 (p &lt; 0.0001), and impact factors in 2023&#x2013;2025 surpassed those of both 2017&#x2013;2020 and 2021&#x2013;2022 (p &lt; 0.0001 for both comparisons).</p>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<title>Discussion</title>
<sec id="s4_1">
<title>Basic overview of the industry</title>
<p>The field of single-cell analysis in tumor immunotherapy has undergone substantial development since the late 20th century. Publication frequency serves as a key indicator for assessing the emergence and evolution of a research hotspot. During its nascent stage, this area garnered limited attention, with fewer than eight articles published annually. A notable turning point occurred in 2016, when researchers began to recognize the potential of single-cell technologies in advancing cancer immunotherapy. This recognition spurred a rapid increase in research activity and scientific output. From 1998 to 2015, publication numbers remained relatively stable with minimal growth. However, between 2016 and 2019, the annual growth rate rose significantly to 27.86%. This upward trajectory accelerated dramatically between 2020 and 2024, reaching an impressive growth rate of 294.18%.</p>
<p>Differences in authorship and citation patterns provide further insights into collaborative practices and the integration of knowledge within this emerging field. The higher number of authors in original research articles likely reflects the multidisciplinary and collaborative nature of experimental work. In contrast, the greater number of references cited in review articles underscores their role in synthesizing rapidly expanding findings to inform clinical and translational applications.</p>
<p>It is important to note that older publications naturally tend to accrue more citations over time, potentially biasing impact assessments. Therefore, incorporating additional metrics&#x2014;such as normalized citation frequency and citation burst analysis&#x2014;offers a more comprehensive and time-adjusted evaluation of scientific influence. These approaches help ensure that recently published high-impact studies are appropriately recognized, despite their limited time to accumulate citations.</p>
<p>The top seven countries contributing to the literature in this field are China, the United States, Germany, the United Kingdom, Japan, South Africa, and France. Among them, the United States, China, and the European Union exhibit the highest total citation counts, publication outputs, and normalized citation frequencies. Notably, the top 100 most-cited publications from the United States have significantly higher citation frequencies and journal impact factors compared to those from the European Union and China, indicating a stronger academic influence and higher international visibility. Although China leads in publication volume, its average citations per article are significantly lower than those of the United States and the European Union, suggesting relatively limited international impact and recognition.</p>
<p>The five institutions with the highest publication frequencies in this field are Fudan University, Sun Yat-sen University, Shanghai Jiao Tong University, Nanjing Medical University, and Central South University. Given current trends, it is anticipated that scholarly output in this area will continue to grow in the coming years. This growth is likely to be accompanied by increasingly close international collaboration, reflecting the global importance and interdisciplinary nature of single-cell analysis in tumor immunotherapy.</p>
<p>Journal analysis highlights the highly interdisciplinary nature of this field, with citation sources primarily originating from foundational biology and tumor immunology journals such as <italic>Cell</italic>, <italic>Cancer Cell</italic>, and <italic>Nature Immunology</italic>. In contrast, knowledge output is mainly concentrated in journals positioned at the intersection of oncology and immunotherapy, including the <italic>Journal for Immunotherapy of Cancer</italic> and <italic>Clinical Cancer Research</italic>.</p>
<p>The strategic diagram further illustrates that topics such as &#x201c;tumor microenvironment heterogeneity&#x201d; and &#x201c;CD8<sup>+</sup> T cell exhaustion&#x201d; exhibit both high centrality and high density, indicating they are motor themes&#x2014;well-developed and influential research areas driving the field forward. In contrast, &#x201c;multimodal single-cell omics integration&#x201d; occupies the quadrant of high centrality but low density, suggesting it is an emerging or transversal theme with substantial potential for future development.</p>
</sec>
<sec id="s4_2">
<title>Mainstreaming research directions</title>
<p>According to keyword analysis, research in this field is primarily driven by terms such as <italic>single-cell RNA sequencing</italic>, <italic>machine learning</italic>, <italic>prognostic models</italic>, <italic>bioinformatics</italic>, <italic>spatial transcriptomics</italic>, <italic>multi-omics</italic>, <italic>tumor microenvironment</italic>, <italic>immune infiltration</italic>, <italic>immune microenvironment</italic>, <italic>heterogeneity</italic>, <italic>macrophage</italic>, <italic>drug sensitivity</italic>, <italic>ferroptosis</italic>, and <italic>immune checkpoints</italic>. Based on our keyword and co-citation clustering analyses, the major research directions can be classified into the following categories:</p>
<p>The frequent appearance of keywords such as <italic>immune microenvironment</italic>, <italic>tumor immune microenvironment</italic>, <italic>heterogeneity</italic>, and <italic>tumor heterogeneity</italic> suggests that immune cell subsets within tumors exhibit considerable heterogeneity. This makes it challenging to identify key cell populations through bulk sequencing techniques. The emergence of <italic>spatial transcriptomics</italic> offers a promising approach to dissect the spatial organization of TME, highlighting its growing relevance in this area. The results of the keyword relevance analysis further validate their association. Representative studies in this cluster, such as Lavin et&#xa0;al. (<italic>Cell</italic>, 2017) (<xref ref-type="bibr" rid="B41">41</xref>) and Li et&#xa0;al. (<italic>Frontiers in Immunology</italic>, 2022) (<xref ref-type="bibr" rid="B42">42</xref>), focus on the spatial distribution and functional dynamics of immune cells&#x2014;including T cells, NK cells, and myeloid cells&#x2014;across tumor tissues, adjacent normal tissues, and peripheral blood. These studies leverage single-cell transcriptomic technologies to construct immune atlases that reflect the evolutionary dynamics of the TME (<xref ref-type="bibr" rid="B23">23</xref>).</p>
<p>The recurrence of keywords such as <italic>immunotherapy</italic>, <italic>cancer immunotherapy</italic>, <italic>immune checkpoints</italic>, and <italic>immune checkpoint inhibitors</italic> highlights the central role of immune checkpoints in therapeutic strategies. Additionally, the frequent mention of <italic>drug sensitivity</italic> reflects growing attention to immune resistance mechanisms. This cluster includes studies exploring the synergistic effects of combining PD-1 with GITR-targeted immunotherapy to restore CD8<sup>+</sup> T cell functionality and maintain memory phenotypes, underscoring the potential of combinatorial approaches to enhance anti-tumor immunity.</p>
<p>This category encompasses the technological evolution of single-cell sequencing platforms, which can be divided into four distinct phases.</p>
<p>Germination Stage (pre-2009): Early efforts focused on adapting high-throughput sequencing to single-cell analysis. However, limitations such as low throughput, high amplification bias, and poor reproducibility hindered progress. The breakthrough came in 2009 with the first successful single-cell mRNA sequencing, marking the inception of modern single-cell transcriptomics (<xref ref-type="bibr" rid="B43">43</xref>). These early methods laid the foundation for profiling immune cell diversity within tumors, which is essential for understanding the mechanisms of immune evasion. Rapid Development Stage (2010&#x2013;2015): A foundational technological framework was established, with advances in cell capture, amplification, library construction, and data analysis. Several widely used platforms emerged during this period, such as Fluidigm C1 and SMART-seq (<xref ref-type="bibr" rid="B44">44</xref>&#x2013;<xref ref-type="bibr" rid="B46">46</xref>), enabling the first studies that revealed the heterogeneity of tumor-infiltrating lymphocytes and identified early biomarkers of immunotherapy response. Maturation and Diversification Stage (2016&#x2013;2019): This period was marked by the expansion of multi-omics capabilities and the profiling of diverse cell types. Notable milestones include the introduction of the 10x Chromium platform by 10x Genomics (Zheng et&#xa0;al., 2017), which set a new industry standard (<xref ref-type="bibr" rid="B37">37</xref>), and the development of Seurat v3 by Stuart et&#xa0;al. (2019), which facilitated data integration across single-cell studies (<xref ref-type="bibr" rid="B47">47</xref>). These advancements enabled large-scale mapping of immune cell states, such as exhausted T cells, contributing to the refinement of immune checkpoint blockade strategies. Spatial transcriptomics, pioneered by Stahl et&#xa0;al. in 2016 (<xref ref-type="bibr" rid="B48">48</xref>), further allowed researchers to visualize immune cell interactions in TME. Refinement and Clinical Translation Stage (2020&#x2013;present): This phase emphasizes higher resolution, multidimensional analysis, and clinical applicability. For example, Penghui Li et&#xa0;al. conducted single-cell analyses of esophageal cancer and adjacent tissues, discovering that a high proportion of HSPA6<sup>+</sup> macrophages is negatively correlated with patient survival outcomes (<xref ref-type="bibr" rid="B28">28</xref>). Yuanyuan Zhang et&#xa0;al. performed a comparative single-cell analysis of immune cell dynamics in triple-negative breast cancer patients treated with paclitaxel, nab-paclitaxel, and their combinations with the anti-PD-L1 antibody atezolizumab, providing a detailed view of immune cell transitions during immunotherapy (<xref ref-type="bibr" rid="B24">24</xref>). Jiaqiang Ma et&#xa0;al. integrated data from 269 patients across 20 cancer types to construct a comprehensive cross-cancer single-cell atlas of tumor-infiltrating B cells, providing a valuable resource for identifying therapeutic targets and biomarkers (<xref ref-type="bibr" rid="B39">39</xref>). Importantly, these single-cell studies have directly shaped the landscape of cancer immunotherapy by identifying tumor-reactive T cell subsets, uncovering predictive markers for PD-1 blockade response, and informing the development of personalized cancer vaccines.</p>
</sec>
<sec id="s4_3">
<title>Single-cell technology pushes immunotherapy to be precise and individualized</title>
<p>The substantial heterogeneity of immune cells within TME remains a major barrier to achieving consistent and durable responses to immunotherapy. Traditional bulk sequencing approaches often mask this complexity, whereas scRNA-seq enables the identification of diverse immune subpopulations&#x2014;including CD8<sup>+</sup> T cells, regulatory T cells (Tregs), M1/M2 macrophages, and exhausted T cells&#x2014;revealing their relative abundances and functional states across individual patients. For example, Sade-Feldman et&#xa0;al. utilized scRNA-seq to profile tumor-infiltrating T cells in melanoma patients treated with immune checkpoint inhibitors. Their findings revealed that responders were enriched for activated CD8<sup>+</sup> T cell phenotypes, whereas non-responders exhibited transcriptional signatures of T cell exhaustion (<xref ref-type="bibr" rid="B36">36</xref>). These insights underscore the potential of constructing immune cell&#x2013;based &#x201c;sensitivity maps&#x201d; to guide personalized therapeutic strategies. Notably, the recent construction of cross-cancer single-cell atlases of infiltrating B cells has attracted widespread attention, further emphasizing the importance of this approach (<xref ref-type="bibr" rid="B30">30</xref>).</p>
<p>Beyond profiling canonical checkpoint molecules such as PD-1 and CTLA-4, scRNA-seq facilitates the discovery of novel immunoregulatory pathways and inhibitory receptors. Emerging checkpoint targets&#x2014;such as LAG3, TIM3, and TIGIT&#x2014;have been identified in dysfunctional T cell subsets within TME and are increasingly recognized as drivers of immune escape (<xref ref-type="bibr" rid="B49">49</xref>). These findings have provided a strong rationale for combinatorial immune checkpoint blockade strategies, including dual targeting approaches (e.g., PD-1 plus LAG3). Furthermore, pathway-level analyses at the single-cell resolution reveal complex immunosuppressive cytokine networks and macrophage polarization imbalances, expanding the scope of potential therapeutic targets beyond traditional immune checkpoints.</p>
<p>By enabling high-resolution profiling of inter-individual variability in immune cell composition and functional states, single-cell technologies significantly advance the personalization of immunotherapy. Several studies have developed immune-related risk scores and T cell functional signatures using scRNA-seq data, demonstrating their predictive value for treatment response (<xref ref-type="bibr" rid="B50">50</xref>). Additionally, integrating scRNA-seq with peripheral blood analyses offers a minimally invasive approach to monitor dynamic immune changes, predict treatment outcomes, and detect potential immune-related adverse events in real time. Moreover, novel plasmablast-like cell signatures developed through the integration of single-cell omics and machine learning have demonstrated remarkable predictive power for immunotherapy efficacy, further demonstrating the potential of single-cell technology for prognostic evaluation of immunotherapy (<xref ref-type="bibr" rid="B23">23</xref>).</p>
</sec>
<sec id="s4_4">
<title>Future research directions and prospects</title>
<p>Despite substantial progress, several critical challenges remain in the application of single-cell technologies to immunotherapy research. Future advancements should focus on the following key areas to fully harness the potential of these tools.</p>
<p>Tumor&#x2013;immune interactions are orchestrated across multiple regulatory layers, including transcriptional, epigenetic, and proteomic mechanisms. Reliance on a single modality, such as scRNA-seq, often yields an incomplete picture of these complex dynamics. Future research should emphasize the integration of scRNA-seq with complementary technologies such as scATAC-seq, CITE-seq (for surface protein profiling), and spatial transcriptomics to construct multidimensional immune atlases (<xref ref-type="bibr" rid="B47">47</xref>). These integrative approaches can illuminate cell&#x2013;cell communication pathways, immunosuppressive networks, and the spatial organization of immune subsets within the tumor microenvironment, thereby informing the rational design of synergistic immunotherapeutic strategies.</p>
<p>The majority of current single-cell studies rely on cross-sectional, single-time-point samples, which limit insights into the temporal dynamics of immune responses. Longitudinal sampling&#x2014;before, during, and after therapy&#x2014;will be crucial for tracking immune cell plasticity, clonal evolution, and mechanisms of immune escape over time (<xref ref-type="bibr" rid="B51">51</xref>). Such dynamic profiling will enable a deeper understanding of resistance pathways and facilitate timely therapeutic adaptations based on real-time immune trajectories.</p>
<p>The complexity and high dimensionality of single-cell datasets pose significant analytical challenges. Artificial intelligence (AI), particularly deep learning algorithms, holds great promise for enhancing cell-type annotation, trajectory inference, and response prediction. Integrating AI into single-cell data analysis pipelines could dramatically improve interpretability, enable robust prognostic modeling, and accelerate the development of clinical decision support systems tailored to individual patients. A compelling example of the integration between single-cell omics and AI is the recent development of deep learning&#x2013;based multimodal models that combine pathology images with genomic and transcriptomic data to predict preoperative lymph node specificity and disease-free survival, illustrating the translational potential of AI-augmented single-cell analysis in precision oncology (<xref ref-type="bibr" rid="B33">33</xref>).</p>
<p>To date, many findings from single-cell studies are derived from small cohorts or retrospective analyses. To ensure clinical relevance, future research must prioritize large-scale, prospective, multi-center validation studies that encompass diverse cancer types and patient populations. Rigorous validation is essential for transforming single-cell&#x2013;based discoveries into actionable biomarkers and therapeutic targets with real-world clinical applicability.</p>
<p>In conclusion, single-cell technologies have become indispensable tools for unraveling the intricacies of the tumor immune microenvironment and refining immunotherapeutic approaches. Continued progress will depend on the integration of longitudinal immune monitoring, multi-omics profiling, AI-enhanced analytics, and robust clinical validation. Together, these efforts will bridge the gap between single-cell research and precision oncology, ultimately contributing to more effective, individualized cancer immunotherapies.</p>
</sec>
<sec id="s4_5">
<title>Strengths and limitations</title>
<p>In this study, we present the first systematic and visually intuitive bibliometric analysis of publications and emerging trends concerning the application of single-cell analysis in cancer immunotherapy. By employing a suite of bibliometric tools, including CiteSpace, VOSviewer, and Bibliometrix, we delineate the evolution of research hotspots, identify influential authors and institutions, and map out potential future directions in this rapidly advancing field. Our findings provide scholars and clinicians with a structured understanding of the current knowledge landscape and offer novel insights to guide subsequent investigations.</p>
<p>Nevertheless, several limitations should be acknowledged. First, due to the technical constraints of existing bibliometric platforms, we were unable to integrate data across multiple databases such as Scopus, PubMed, CNKI, and patent repositories in both Chinese and English. Consequently, our analysis was limited to WOSCC, which, while high in quality and comprehensiveness, does not fully capture all relevant literature. Future studies could benefit from more robust and integrative platforms capable of incorporating multi-source bibliographic data. Second, although meticulous search strategies were employed, the retrieval process inevitably included some irrelevant publications and may have omitted others due to ambiguous, inconsistent, or non-standardized titles and keywords. This highlights the inherent trade-off between sensitivity and specificity in bibliometric data collection. Third, the use of multiple bibliometric tools&#x2014;each with different algorithms and visualization frameworks&#x2014;may lead to slight variations in analytical outcomes. As with all quantitative analyses, these methodological differences, combined with inherent biases in citation behaviors, may influence the interpretation of results. Fourth, in this study, we used the 2023 JCR impact factor to represent journal influence, rather than the impact factor corresponding to the year of publication. This may limit the temporal accuracy of journal impact assessment. Future studies could consider incorporating year-specific impact factors or normalized citation metrics to allow for a more time-sensitive evaluation. Lastly, although we employed meticulous and refined search strategies, the retrieval process may have inevitably included irrelevant publications and omitted some relevant ones due to ambiguous, inconsistent, or non-standardized titles and keywords. This reflects the inherent trade-off between sensitivity and specificity in bibliometric data collection.</p>
<p>Despite these limitations, our study provides a timely and valuable overview of the scientific dynamics in single-cell&#x2013;based cancer immunotherapy. With the continuous evolution of bibliometric methodologies and the expansion of relevant databases, future bibliometric analyses will further enhance our understanding of this field, facilitating the identification of cutting-edge themes and promoting interdisciplinary collaboration.</p>
</sec>
</sec>
<sec id="s5" sec-type="conclusion">
<title>Conclusion</title>
<p>This study offers the first comprehensive and scientifically grounded bibliometric overview of global research trends related to the application of single-cell analysis in cancer immunotherapy. By mapping the intellectual landscape and identifying emerging hotspots, our findings provide researchers with a clearer understanding of the field&#x2019;s evolution and valuable guidance for future innovation. As AI continues to advance, the interdisciplinary integration of AI with multi-omics data is expected to catalyze the development of medical informatics. This convergence holds great promise for unraveling the mechanistic underpinnings of cancer immunotherapy and enhancing the precision of omics-driven strategies. Looking forward, the acceleration of integration between medicine and informatics will be critical. Priority should be given to strengthening links between clinical application, basic research, technological development, and standardization. Such efforts will support the modernization of medical informatics and promote translational outcomes. Within the framework of China&#x2019;s &#x201c;Belt and Road&#x201d; Initiative and other favorable policy environments, enhanced international and interdisciplinary collaboration among researchers, institutions, and countries is anticipated. These synergies will foster deeper, more systematic investigations and ultimately contribute to delivering precise and personalized clinical guidance for cancer immunotherapy.</p>
</sec>
</body>
<back>
<sec id="s6" sec-type="data-availability">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="supplementary-material" rid="SF1">
<bold>Supplementary Material</bold>
</xref>, further inquiries can be directed to the corresponding author/s.</p>
</sec>
<sec id="s7" sec-type="author-contributions">
<title>Author contributions</title>
<p>ZL: Conceptualization, Data curation, Formal Analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. QH: Formal Analysis, Funding acquisition, Methodology, Software, Visualization, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. ZH: Methodology, Software, Validation, Visualization, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. SZ: Project administration, Supervision, Validation, Visualization, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. HG: Data curation, Investigation, Methodology, Software, Validation, Visualization, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. HLL: Data curation, Funding acquisition, Software, Supervision, Validation, Visualization, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. XG: Data curation, Funding acquisition, Investigation, Software, Supervision, Validation, Visualization, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. HRL: Conceptualization, Formal Analysis, Resources, Supervision, Validation, Visualization, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. CZ: Conceptualization, Investigation, Methodology, Project administration, Supervision, Validation, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing.</p>
</sec>
<sec id="s8" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare financial support was received for the research and/or publication of this article. This work was supported by the Basic Research Program of Shanxi Province (Free Exploration) (No. 202203021211015, 202203021212032, 202203021212036, 202403021222446).</p>
</sec>
<sec id="s9" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s10" sec-type="ai-statement">
<title>Generative AI Statement</title>
<p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p>
</sec>
<sec id="s11" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s12" sec-type="supplementary-material">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2025.1640224/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fimmu.2025.1640224/full#supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="DataSheet1.zip" id="SF1" mimetype="application/zip">
<label>Supplementary Table&#xa0;1</label>
<caption>
<p>Characteristic information form of all included papers.</p>
</caption>
</supplementary-material>
<supplementary-material xlink:href="DataSheet2.zip" id="SF2" mimetype="application/zip">
<label>Supplementary Figure&#xa0;1</label>
<caption>
<p>Analysis of total citation frequency, publication volume and normalized citation frequency of top 21 highly cited countries.</p>
</caption>
</supplementary-material>
<supplementary-material xlink:href="DataSheet3.zip" id="SF3" mimetype="application/zip">
<label>Supplementary Table&#xa0;2</label>
<caption>
<p>Top 100 most-cited publications from the United States, China, and the European Union.</p>
</caption>
</supplementary-material>
<supplementary-material xlink:href="DataSheet4.zip" id="SF4" mimetype="application/zip">
<label>Supplementary Table&#xa0;3</label>
<caption>
<p>Citation cluster naming results from the literature co-citation analysis.</p>
</caption>
</supplementary-material>
<supplementary-material xlink:href="DataSheet5.zip" id="SF5" mimetype="application/zip">
<label>Supplementary Table&#xa0;4</label>
<caption>
<p>Keyword co-citation cluster naming results.</p>
</caption>
</supplementary-material>
<supplementary-material xlink:href="DataSheet6.zip" id="SF6" mimetype="application/zip">
<label>Supplementary Figure&#xa0;2</label>
<caption>
<p>Results of the relevance analysis for key author keywords.</p>
</caption>
</supplementary-material>
</sec>
<fn-group>
<title>Abbreviations</title>
<fn fn-type="abbr" id="abbrev1">
<p>AI, Artificial intelligence; CITE-seq, Cellular Indexing of Transcriptomes and Epitopes by sequencing; scATAC-seq, single-cell ATAC sequencing; scATAC-seq, single-cell ATAC sequencing; JCR, Journal Citation Reports; LLR, Log-Likelihood Ratio; LSI, Semantic Indexing; TME, tumor microenvironment; WOSCC, Web of Science Core Collection; JCR, Journal Citation Reports.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname> <given-names>M</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>P</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>B</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Xia</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Nie</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Improved efficacy of concurrent anti-PD1 antibody plus AVD versus ABVD in patients with newly diagnosed early unfavorable and advanced stage classic hodgkin lymphoma: A retrospective matched cohort study</article-title>. <source>Cancer Immunol Immunother</source>. (<year>2025</year>) <volume>74</volume>:<fpage>206</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00262-025-04041-z</pub-id>, PMID: <pub-id pub-id-type="pmid">40372486</pub-id></citation></ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barroso-Sousa</surname> <given-names>R</given-names>
</name>
<name>
<surname>Zanudo</surname> <given-names>JGT</given-names>
</name>
<name>
<surname>Li</surname> <given-names>T</given-names>
</name>
<name>
<surname>Reddy</surname> <given-names>SM</given-names>
</name>
<name>
<surname>Emens</surname> <given-names>LA</given-names>
</name>
<name>
<surname>Kuntz</surname> <given-names>TM</given-names>
</name>
<etal/>
</person-group>. <article-title>Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: A phase II trial (NIMBUS)</article-title>. <source>Nat Commun</source>. (<year>2025</year>) <volume>16</volume>:<fpage>4430</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41467-025-59695-1</pub-id>, PMID: <pub-id pub-id-type="pmid">40360544</pub-id></citation></ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Li</surname> <given-names>J</given-names>
</name>
<name>
<surname>Xuan</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>Prospects for &#x3b3;&#x3b4; T cells and chimeric antigen receptor &#x3b3;&#x3b4; T cells in cancer immunotherapy</article-title>. <source>Front Immunol</source>. (<year>2025</year>) <volume>16</volume>:<elocation-id>1554541</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2025.1554541</pub-id>, PMID: <pub-id pub-id-type="pmid">40370457</pub-id></citation></ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jia</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>L</given-names>
</name>
<name>
<surname>Shan</surname> <given-names>B</given-names>
</name>
</person-group>. <article-title>Future of immune checkpoint inhibitors: Focus on tumor immune microenvironment</article-title>. <source>Ann Transl Med</source>. (<year>2020</year>) <volume>8</volume>:<fpage>1095</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.21037/atm-20-3735</pub-id>, PMID: <pub-id pub-id-type="pmid">33145314</pub-id></citation></ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>An</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Duan</surname> <given-names>L</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>F</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Role of CD4+ T cells in cancer immunity: A single-cell sequencing exploration of tumor microenvironment</article-title>. <source>J Transl Med</source>. (<year>2025</year>) <volume>23</volume>:<fpage>179</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12967-025-06167-1</pub-id>, PMID: <pub-id pub-id-type="pmid">39953548</pub-id></citation></ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname> <given-names>C</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>L</given-names>
</name>
<name>
<surname>Yoo</surname> <given-names>J-K</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>H</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing</article-title>. <source>Cell</source>. (<year>2017</year>) <volume>169</volume>:<fpage>1342</fpage>&#x2013;<lpage>1356.e16</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cell.2017.05.035</pub-id>, PMID: <pub-id pub-id-type="pmid">28622514</pub-id></citation></ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname> <given-names>S</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>R</given-names>
</name>
<name>
<surname>Xing</surname> <given-names>B</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells</article-title>. <source>Cell</source>. (<year>2021</year>) <volume>184</volume>:<fpage>792</fpage>&#x2013;<lpage>809.e23</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cell.2021.01.010</pub-id>, PMID: <pub-id pub-id-type="pmid">33545035</pub-id></citation></ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Fu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>H</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>H</given-names>
</name>
<name>
<surname>Guan</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Analyzing the research landscape: Mapping frontiers and hot spots in anti-cancer research using bibliometric analysis and research network pharmacology</article-title>. <source>Front Pharmacol</source> (<year>2023</year>) <volume>14</volume>:<elocation-id>1256188</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fphar.2023.1256188</pub-id>, PMID: <pub-id pub-id-type="pmid">37745055</pub-id></citation></ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Feng</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Xiao</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Bibliometric analysis and visualization of connexin 43 in the field of solid tumor research(2000-2024)</article-title>. <source>Front Immunol</source>. (<year>2025</year>) <volume>16</volume>:<elocation-id>1588828</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2025.1588828</pub-id>, PMID: <pub-id pub-id-type="pmid">40416989</pub-id></citation></ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ren</surname> <given-names>C</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>T</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Song</surname> <given-names>X</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Trends in research on the P2X7 receptor: A bibliometric and visualization analysis</article-title>. <source>J Inflammation Res</source>. (<year>2025</year>) <volume>18</volume>:<page-range>6349&#x2013;62</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2147/JIR.S522380</pub-id>, PMID: <pub-id pub-id-type="pmid">40395554</pub-id></citation></ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aria</surname> <given-names>M</given-names>
</name>
<name>
<surname>Cuccurullo</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>
<italic>bibliometrix</italic>: An R-tool for comprehensive science mapping analysis</article-title>. <source>J Informetrics</source>. (<year>2017</year>) <volume>11</volume>:<page-range>959&#x2013;75</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.joi.2017.08.007</pub-id>
</citation></ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cobo</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>L&#xf3;pez-Herrera</surname> <given-names>AG</given-names>
</name>
<name>
<surname>Herrera-Viedma</surname> <given-names>E</given-names>
</name>
<name>
<surname>Herrera</surname> <given-names>F</given-names>
</name>
</person-group>. <article-title>An approach for detecting, quantifying, and visualizing the evolution of a research field: A practical application to the fuzzy sets theory field</article-title>. <source>J Informetrics</source>. (<year>2011</year>) <volume>5</volume>:<page-range>146&#x2013;66</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.joi.2010.10.002</pub-id>
</citation></ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aria</surname> <given-names>M</given-names>
</name>
<name>
<surname>Misuraca</surname> <given-names>M</given-names>
</name>
<name>
<surname>Spano</surname> <given-names>M.</given-names>
</name>
</person-group> <article-title>Mapping the evolution of social research and data science on 30 years of social indicators research</article-title>. <source>Soc Indic Res.</source> (<year>2020</year>) <volume>149</volume>:<page-range>803&#x2013;31</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s11205-020-02281&#x2013;3</pub-id>
</citation></ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Eck</surname> <given-names>NJ</given-names>
</name>
<name>
<surname>Waltman</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Software survey: VOSviewer, a computer program for bibliometric mapping</article-title>. <source>Scientometrics</source>. (<year>2010</year>) <volume>84</volume>:<page-range>523&#x2013;38</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s11192-009-0146-3</pub-id>, PMID: <pub-id pub-id-type="pmid">20585380</pub-id></citation></ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hassan-Montero</surname> <given-names>Y</given-names>
</name>
<name>
<surname>De-Moya-Aneg&#xf3;n</surname> <given-names>F</given-names>
</name>
<name>
<surname>Guerrero-Bote</surname> <given-names>VP</given-names>
</name>
</person-group>. <article-title>SCImago graphica: A new tool for exploring and visually communicating data</article-title>. <source>EPI</source>. (<year>2022</year>) <volume>31</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3145/epi.2022.sep.02</pub-id>
</citation></ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shannon</surname> <given-names>P</given-names>
</name>
<name>
<surname>Markiel</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ozier</surname> <given-names>O</given-names>
</name>
<name>
<surname>Baliga</surname> <given-names>NS</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>JT</given-names>
</name>
<name>
<surname>Ramage</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Cytoscape: A software environment for integrated models of biomolecular interaction networks</article-title>. <source>Genome Res</source>. (<year>2003</year>) <volume>13</volume>:<page-range>2498&#x2013;504</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1101/gr.1239303</pub-id>, PMID: <pub-id pub-id-type="pmid">14597658</pub-id></citation></ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Searching for intellectual turning points: Progressive knowledge domain visualization</article-title>. <source>Proc Natl Acad Sci U.S.A</source>. (<year>2004</year>) <volume>101 Suppl 1</volume>:<page-range>5303&#x2013;10</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.0307513100</pub-id>, PMID: <pub-id pub-id-type="pmid">14724295</pub-id></citation></ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patel</surname> <given-names>AP</given-names>
</name>
<name>
<surname>Tirosh</surname> <given-names>I</given-names>
</name>
<name>
<surname>Trombetta</surname> <given-names>JJ</given-names>
</name>
<name>
<surname>Shalek</surname> <given-names>AK</given-names>
</name>
<name>
<surname>Gillespie</surname> <given-names>SM</given-names>
</name>
<name>
<surname>Wakimoto</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma</article-title>. <source>Science</source>. (<year>2014</year>) <volume>344</volume>:<page-range>1396&#x2013;401</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/science.1254257</pub-id>, PMID: <pub-id pub-id-type="pmid">24925914</pub-id></citation></ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Visser</surname> <given-names>KE</given-names>
</name>
<name>
<surname>Joyce</surname> <given-names>JA</given-names>
</name>
</person-group>. <article-title>The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth</article-title>. <source>Cancer Cell</source>. (<year>2023</year>) <volume>41</volume>:<fpage>374</fpage>&#x2013;<lpage>403</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ccell.2023.02.016</pub-id>, PMID: <pub-id pub-id-type="pmid">36917948</pub-id></citation></ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tirosh</surname> <given-names>I</given-names>
</name>
<name>
<surname>Izar</surname> <given-names>B</given-names>
</name>
<name>
<surname>Prakadan</surname> <given-names>SM</given-names>
</name>
<name>
<surname>Wadsworth</surname> <given-names>MH</given-names>
</name>
<name>
<surname>Treacy</surname> <given-names>D</given-names>
</name>
<name>
<surname>Trombetta</surname> <given-names>JJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq</article-title>. <source>Science</source>. (<year>2016</year>) <volume>352</volume>:<page-range>189&#x2013;96</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/science.aad0501</pub-id>, PMID: <pub-id pub-id-type="pmid">27124452</pub-id></citation></ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Skrzypczynska</surname> <given-names>KM</given-names>
</name>
<name>
<surname>Fang</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>W</given-names>
</name>
<name>
<surname>O&#x2019;Brien</surname> <given-names>SA</given-names>
</name>
<etal/>
</person-group>. <article-title>Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer</article-title>. <source>Cell</source>. (<year>2020</year>) <volume>181</volume>:<fpage>442</fpage>&#x2013;<lpage>459.e29</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cell.2020.03.048</pub-id>, PMID: <pub-id pub-id-type="pmid">32302573</pub-id></citation></ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>C</given-names>
</name>
<name>
<surname>Song</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Q</given-names>
</name>
<etal/>
</person-group>. <article-title>Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing</article-title>. <source>Nat Med</source>. (<year>2018</year>) <volume>24</volume>:<page-range>978&#x2013;85</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41591-018-0045-3</pub-id>, PMID: <pub-id pub-id-type="pmid">29942094</pub-id></citation></ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ye</surname> <given-names>B</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>A</given-names>
</name>
<name>
<surname>Liang</surname> <given-names>F</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Liang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>P</given-names>
</name>
</person-group>. <article-title>Navigating the immune landscape with plasma cells: A pan-cancer signature for precision immunotherapy</article-title>. <source>Biofactors.</source> (<year>2025</year>) <volume>51</volume>:<elocation-id>e2142</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/biof.2142</pub-id>, PMID: <pub-id pub-id-type="pmid">39495620</pub-id></citation></ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>H</given-names>
</name>
<name>
<surname>Mo</surname> <given-names>H</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>N</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>X</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer</article-title>. <source>Cancer Cell</source>. (<year>2025</year>) <volume>43</volume>:<fpage>446</fpage>&#x2013;<lpage>463.e7</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ccell.2025.01.007</pub-id>, PMID: <pub-id pub-id-type="pmid">39919737</pub-id></citation></ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>H</given-names>
</name>
<name>
<surname>Cao</surname> <given-names>R</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>L</given-names>
</name>
<name>
<surname>Dang</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Decoding the tumor microenvironment and molecular mechanism: Unraveling cervical cancer subpopulations and prognostic signatures through scRNA-seq and bulk RNA-seq analyses</article-title>. <source>Front Immunol</source>. (<year>2024</year>) <volume>15</volume>:<elocation-id>1351287</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2024.1351287</pub-id>, PMID: <pub-id pub-id-type="pmid">38482016</pub-id></citation></ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xing</surname> <given-names>J</given-names>
</name>
<name>
<surname>Cai</surname> <given-names>H</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>L</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>H</given-names>
</name>
<name>
<surname>Song</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Examining the function of macrophage oxidative stress response and immune system in glioblastoma multiforme through analysis of single-cell transcriptomics</article-title>. <source>Front Immunol</source>. (<year>2024</year>) <volume>14</volume>:<elocation-id>1288137</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2023.1288137</pub-id>, PMID: <pub-id pub-id-type="pmid">38274828</pub-id></citation></ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shao</surname> <given-names>W</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Xiahou</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>F</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Single-cell RNA sequencing reveals that MYBL2 in Malignant epithelial cells is involved in the development and progression of ovarian cancer</article-title>. <source>Front Immunol</source>. (<year>2024</year>) <volume>15</volume>:<elocation-id>1438198</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2024.1438198</pub-id>, PMID: <pub-id pub-id-type="pmid">39136009</pub-id></citation></ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>P</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>X</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>D</given-names>
</name>
<name>
<surname>Gu</surname> <given-names>X</given-names>
</name>
</person-group>. <article-title>Identification and characterization of prognostic macrophage subpopulations for human esophageal carcinoma</article-title>. <source>Curr Med Chem</source>. (<year>2025</year>) <volume>32</volume>:<page-range>123&#x2013;35</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2174/0109298673284207240108105724</pub-id>, PMID: <pub-id pub-id-type="pmid">38362682</pub-id></citation></ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Xun</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>K</given-names>
</name>
<name>
<surname>Liang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy</article-title>. <source>J Hepatol</source>. (<year>2023</year>) <volume>78</volume>:<page-range>770&#x2013;82</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jhep.2023.01.011</pub-id>, PMID: <pub-id pub-id-type="pmid">36708811</pub-id></citation></ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>L</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>T</given-names>
</name>
<name>
<surname>Song</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>A blueprint for tumor-infiltrating B cells across human cancers</article-title>. <source>Science</source>. (<year>2024</year>) <volume>384</volume>:<elocation-id>eadj4857</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/science.adj4857</pub-id>, PMID: <pub-id pub-id-type="pmid">38696569</pub-id></citation></ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>J</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Song</surname> <given-names>G</given-names>
</name>
<name>
<surname>Rao</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Spatiotemporal immune landscape of colorectal cancer liver metastasis at single-cell level</article-title>. <source>Cancer Discov</source>. (<year>2022</year>) <volume>12</volume>:<page-range>134&#x2013;53</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1158/2159-8290.CD-21-0316</pub-id>, PMID: <pub-id pub-id-type="pmid">34417225</pub-id></citation></ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname> <given-names>S</given-names>
</name>
<name>
<surname>Jin</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Nazaret</surname> <given-names>A</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>L</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>X</given-names>
</name>
<name>
<surname>Rampersaud</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Starfysh integrates spatial transcriptomic and histologic data to reveal heterogeneous tumor&#x2013;immune hubs</article-title>. <source>Nat Biotechnol</source>. (<year>2025</year>) <volume>43</volume>:<page-range>223&#x2013;35</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41587-024-02173-8</pub-id>, PMID: <pub-id pub-id-type="pmid">38514799</pub-id></citation></ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Ouyang</surname> <given-names>W</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Jia</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Artificial intelligence-based multi-modal multi-tasks analysis reveals tumor molecular heterogeneity, predicts preoperative lymph node metastasis and prognosis in papillary thyroid carcinoma: A retrospective study</article-title>. <source>Int J Surg</source>. (<year>2025</year>) <volume>111</volume>:<page-range>839&#x2013;56</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/JS9.0000000000001875</pub-id>, PMID: <pub-id pub-id-type="pmid">38990290</pub-id></citation></ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yarchoan</surname> <given-names>M</given-names>
</name>
<name>
<surname>Gane</surname> <given-names>EJ</given-names>
</name>
<name>
<surname>Marron</surname> <given-names>TU</given-names>
</name>
<name>
<surname>Perales-Linares</surname> <given-names>R</given-names>
</name>
<name>
<surname>Yan</surname> <given-names>J</given-names>
</name>
<name>
<surname>Cooch</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: A phase 1/2 trial</article-title>. <source>Nat Med</source>. (<year>2024</year>) <volume>30</volume>:<page-range>1044&#x2013;53</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41591-024-02894-y</pub-id>, PMID: <pub-id pub-id-type="pmid">38584166</pub-id></citation></ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lambrechts</surname> <given-names>D</given-names>
</name>
<name>
<surname>Wauters</surname> <given-names>E</given-names>
</name>
<name>
<surname>Boeckx</surname> <given-names>B</given-names>
</name>
<name>
<surname>Aibar</surname> <given-names>S</given-names>
</name>
<name>
<surname>Nittner</surname> <given-names>D</given-names>
</name>
<name>
<surname>Burton</surname> <given-names>O</given-names>
</name>
<etal/>
</person-group>. <article-title>Phenotype molding of stromal cells in the lung tumor microenvironment</article-title>. <source>Nat Med</source>. (<year>2018</year>) <volume>24</volume>:<page-range>1277&#x2013;89</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41591-018-0096-5</pub-id>, PMID: <pub-id pub-id-type="pmid">29988129</pub-id></citation></ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sade-Feldman</surname> <given-names>M</given-names>
</name>
<name>
<surname>Yizhak</surname> <given-names>K</given-names>
</name>
<name>
<surname>Bjorgaard</surname> <given-names>SL</given-names>
</name>
<name>
<surname>Ray</surname> <given-names>JP</given-names>
</name>
<name>
<surname>de Boer</surname> <given-names>CG</given-names>
</name>
<name>
<surname>Jenkins</surname> <given-names>RW</given-names>
</name>
<etal/>
</person-group>. <article-title>Defining T cell states associated with response to checkpoint immunotherapy in melanoma</article-title>. <source>Cell</source>. (<year>2019</year>) <volume>176</volume>:<fpage>404</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cell.2018.12.034</pub-id>, PMID: <pub-id pub-id-type="pmid">30633907</pub-id></citation></ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname> <given-names>GXY</given-names>
</name>
<name>
<surname>Terry</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Belgrader</surname> <given-names>P</given-names>
</name>
<name>
<surname>Ryvkin</surname> <given-names>P</given-names>
</name>
<name>
<surname>Bent</surname> <given-names>ZW</given-names>
</name>
<name>
<surname>Wilson</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Massively parallel digital transcriptional profiling of single cells</article-title>. <source>Nat Commun</source>. (<year>2017</year>) <volume>8</volume>:<elocation-id>14049</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/ncomms14049</pub-id>, PMID: <pub-id pub-id-type="pmid">28091601</pub-id></citation></ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Newman</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Steen</surname> <given-names>CB</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>CL</given-names>
</name>
<name>
<surname>Gentles</surname> <given-names>AJ</given-names>
</name>
<name>
<surname>Chaudhuri</surname> <given-names>AA</given-names>
</name>
<name>
<surname>Scherer</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Determining cell type abundance and expression from bulk tissues with digital cytometry</article-title>. <source>Nat Biotechnol</source>. (<year>2019</year>) <volume>37</volume>:<page-range>773&#x2013;82</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41587-019-0114-2</pub-id>, PMID: <pub-id pub-id-type="pmid">31061481</pub-id></citation></ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Helmink</surname> <given-names>BA</given-names>
</name>
<name>
<surname>Reddy</surname> <given-names>SM</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Basar</surname> <given-names>R</given-names>
</name>
<name>
<surname>Thakur</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>B cells and tertiary lymphoid structures promote immunotherapy response</article-title>. <source>Nature</source>. (<year>2020</year>) <volume>577</volume>:<page-range>549&#x2013;55</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41586-019-1922-8</pub-id>, PMID: <pub-id pub-id-type="pmid">31942075</pub-id></citation></ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Puram</surname> <given-names>SV</given-names>
</name>
<name>
<surname>Tirosh</surname> <given-names>I</given-names>
</name>
<name>
<surname>Parikh</surname> <given-names>AS</given-names>
</name>
<name>
<surname>Patel</surname> <given-names>AP</given-names>
</name>
<name>
<surname>Yizhak</surname> <given-names>K</given-names>
</name>
<name>
<surname>Gillespie</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer</article-title>. <source>Cell</source> (<year>2017</year>) <volume>171</volume>:<page-range>1611&#x2013;24.e24</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cell.2017.10.044</pub-id>, PMID: <pub-id pub-id-type="pmid">29198524</pub-id></citation></ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lavin</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Kobayashi</surname> <given-names>S</given-names>
</name>
<name>
<surname>Leader</surname> <given-names>A</given-names>
</name>
<name>
<surname>Amir</surname> <given-names>E-AD</given-names>
</name>
<name>
<surname>Elefant</surname> <given-names>N</given-names>
</name>
<name>
<surname>Bigenwald</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses</article-title>. <source>Cell</source>. (<year>2017</year>) <volume>169</volume>:<fpage>750</fpage>&#x2013;<lpage>765.e17</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cell.2017.04.014</pub-id>, PMID: <pub-id pub-id-type="pmid">28475900</pub-id></citation></ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>C</given-names>
</name>
<name>
<surname>Hua</surname> <given-names>K</given-names>
</name>
</person-group>. <article-title>Dissecting the single-cell transcriptome network of immune environment underlying cervical premalignant lesion, cervical cancer and metastatic lymph nodes</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>897366</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2022.897366</pub-id>, PMID: <pub-id pub-id-type="pmid">35812401</pub-id></citation></ref>
<ref id="B43">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname> <given-names>F</given-names>
</name>
<name>
<surname>Barbacioru</surname> <given-names>C</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Nordman</surname> <given-names>E</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>C</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>mRNA-seq whole-transcriptome analysis of a single cell</article-title>. <source>Nat Methods</source>. (<year>2009</year>) <volume>6</volume>:<page-range>377&#x2013;82</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nmeth.1315</pub-id>, PMID: <pub-id pub-id-type="pmid">19349980</pub-id></citation></ref>
<ref id="B44">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Macosko</surname> <given-names>EZ</given-names>
</name>
<name>
<surname>Basu</surname> <given-names>A</given-names>
</name>
<name>
<surname>Satija</surname> <given-names>R</given-names>
</name>
<name>
<surname>Nemesh</surname> <given-names>J</given-names>
</name>
<name>
<surname>Shekhar</surname> <given-names>K</given-names>
</name>
<name>
<surname>Goldman</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets</article-title>. <source>Cell</source>. (<year>2015</year>) <volume>161</volume>:<page-range>1202&#x2013;14</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cell.2015.05.002</pub-id>, PMID: <pub-id pub-id-type="pmid">26000488</pub-id></citation></ref>
<ref id="B45">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Picelli</surname> <given-names>S</given-names>
</name>
<name>
<surname>Bj&#xf6;rklund</surname> <given-names>&#xc5;K</given-names>
</name>
<name>
<surname>Faridani</surname> <given-names>OR</given-names>
</name>
<name>
<surname>Sagasser</surname> <given-names>S</given-names>
</name>
<name>
<surname>Winberg</surname> <given-names>G</given-names>
</name>
<name>
<surname>Sandberg</surname> <given-names>R</given-names>
</name>
</person-group>. <article-title>Smart-seq2 for sensitive full-length transcriptome profiling in single cells</article-title>. <source>Nat Methods</source>. (<year>2013</year>) <volume>10</volume>:<page-range>1096&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nmeth.2639</pub-id>, PMID: <pub-id pub-id-type="pmid">24056875</pub-id></citation></ref>
<ref id="B46">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Islam</surname> <given-names>S</given-names>
</name>
<name>
<surname>Kj&#xe4;llquist</surname> <given-names>U</given-names>
</name>
<name>
<surname>Moliner</surname> <given-names>A</given-names>
</name>
<name>
<surname>Zajac</surname> <given-names>P</given-names>
</name>
<name>
<surname>Fan</surname> <given-names>J-B</given-names>
</name>
<name>
<surname>L&#xf6;nnerberg</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Characterization of the single-cell transcriptional landscape by highly multiplex RNA-seq</article-title>. <source>Genome Res</source>. (<year>2011</year>) <volume>21</volume>:<page-range>1160&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1101/gr.110882.110</pub-id>, PMID: <pub-id pub-id-type="pmid">21543516</pub-id></citation></ref>
<ref id="B47">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stuart</surname> <given-names>T</given-names>
</name>
<name>
<surname>Butler</surname> <given-names>A</given-names>
</name>
<name>
<surname>Hoffman</surname> <given-names>P</given-names>
</name>
<name>
<surname>Hafemeister</surname> <given-names>C</given-names>
</name>
<name>
<surname>Papalexi</surname> <given-names>E</given-names>
</name>
<name>
<surname>Mauck</surname> <given-names>WM</given-names>
</name>
<etal/>
</person-group>. <article-title>Comprehensive integration of single-cell data</article-title>. <source>Cell</source>. (<year>2019</year>) <volume>177</volume>:<fpage>1888</fpage>&#x2013;<lpage>1902.e21</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cell.2019.05.031</pub-id>, PMID: <pub-id pub-id-type="pmid">31178118</pub-id></citation></ref>
<ref id="B48">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>St&#xe5;hl</surname> <given-names>PL</given-names>
</name>
<name>
<surname>Salm&#xe9;n</surname> <given-names>F</given-names>
</name>
<name>
<surname>Vickovic</surname> <given-names>S</given-names>
</name>
<name>
<surname>Lundmark</surname> <given-names>A</given-names>
</name>
<name>
<surname>Navarro</surname> <given-names>JF</given-names>
</name>
<name>
<surname>Magnusson</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Visualization and analysis of gene expression in tissue sections by spatial transcriptomics</article-title>. <source>Science</source>. (<year>2016</year>) <volume>353</volume>:<fpage>78</fpage>&#x2013;<lpage>82</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/science.aaf2403</pub-id>, PMID: <pub-id pub-id-type="pmid">27365449</pub-id></citation></ref>
<ref id="B49">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thommen</surname> <given-names>DS</given-names>
</name>
<name>
<surname>Schumacher</surname> <given-names>TN</given-names>
</name>
</person-group>. <article-title>T cell dysfunction in cancer</article-title>. <source>Cancer Cell</source>. (<year>2018</year>) <volume>33</volume>:<page-range>547&#x2013;62</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ccell.2018.03.012</pub-id>, PMID: <pub-id pub-id-type="pmid">29634943</pub-id></citation></ref>
<ref id="B50">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Fang</surname> <given-names>Q</given-names>
</name>
<etal/>
</person-group>. <article-title>Lineage tracking reveals dynamic relationships of T cells in colorectal cancer</article-title>. <source>Nature</source>. (<year>2018</year>) <volume>564</volume>:<page-range>268&#x2013;72</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41586-018-0694-x</pub-id>, PMID: <pub-id pub-id-type="pmid">30479382</pub-id></citation></ref>
<ref id="B51">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yost</surname> <given-names>KE</given-names>
</name>
<name>
<surname>Satpathy</surname> <given-names>AT</given-names>
</name>
<name>
<surname>Wells</surname> <given-names>DK</given-names>
</name>
<name>
<surname>Qi</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Kageyama</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Clonal replacement of tumor-specific T cells following PD-1 blockade</article-title>. <source>Nat Med</source>. (<year>2019</year>) <volume>25</volume>:<page-range>1251&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41591-019-0522-3</pub-id>, PMID: <pub-id pub-id-type="pmid">31359002</pub-id></citation></ref>
</ref-list>
</back>
</article>